<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02607865</url>
  </required_header>
  <id_info>
    <org_study_id>NN9924-4222</org_study_id>
    <secondary_id>2015-001351-71</secondary_id>
    <secondary_id>U1111-1168-4339</secondary_id>
    <secondary_id>JAPIC</secondary_id>
    <nct_id>NCT02607865</nct_id>
  </id_info>
  <brief_title>Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes</brief_title>
  <acronym>PIONEER 3</acronym>
  <official_title>Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted globally. The aim of the trial is to investigate efficacy and
      long-term safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2016</start_date>
  <completion_date type="Actual">March 28, 2018</completion_date>
  <primary_completion_date type="Actual">February 14, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c: Week 26</measure>
    <time_frame>Week 0, week 26</time_frame>
    <description>Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated at week 26. The endpoint was evaluated based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product. The endpoint was also evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was on treatment with trial product, excluding any period after initiation of rescue medication and/or premature trial product discontinuation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight: Week 26</measure>
    <time_frame>Week 0, week 26</time_frame>
    <description>Change from baseline (week 0) in body weight was evaluated at week 26. The endpoint was evaluated based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product. The endpoint was also evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was on treatment with trial product, excluding any period after initiation of rescue medication and/or premature trial product discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c: Weeks 52 and 78</measure>
    <time_frame>Week 0, week 52, week 78</time_frame>
    <description>Change from baseline (week 0) in HbA1c was evaluated at weeks 52 and 78. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight (kg): Weeks 52 and 78</measure>
    <time_frame>Week 0, week 52, week 78</time_frame>
    <description>Change from baseline (week 0) in body weight was evaluated at weeks 52 and 78. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight (%)</measure>
    <time_frame>Week 0, week 26, week 52, week 78</time_frame>
    <description>Relative change from baseline (week 0) in body weight (kg) was evaluated at weeks 26, 52 and 78. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FPG</measure>
    <time_frame>Week 0, week 26, week 52, week 78</time_frame>
    <description>Change from baseline (week 0) in fasting plasma glucose (FPG) was evaluated at weeks 26, 52 and 78. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BMI</measure>
    <time_frame>Week 0, week 26, week 52, week 78</time_frame>
    <description>Change from baseline (week 0) in body mass index (BMI) was evaluated at weeks 26, 52 and 78. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Waist Circumference</measure>
    <time_frame>Week 0, week 26, week 52, week 78</time_frame>
    <description>Change from baseline (week 0) in waist circumference was evaluated at weeks 26, 52 and 78. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Cholesterol (Ratio to Baseline)</measure>
    <time_frame>Week 0, week 26, week 52, week 78</time_frame>
    <description>Change from baseline (week 0) in total cholesterol (mmol/L) at weeks 26, 52 and 78 is presented as ratio to baseline. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LDL Cholesterol (Ratio to Baseline)</measure>
    <time_frame>Week 0, week 26, week 52, week 78</time_frame>
    <description>Change from baseline (week 0) in low-density lipoprotein (LDL) cholesterol (mmol/L) at weeks 26, 52 and 78 is presented as ratio to baseline. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in VLDL Cholesterol (Ratio to Baseline)</measure>
    <time_frame>Week 0, week 26, week 52, week 78</time_frame>
    <description>Change from baseline (week 0) in very-low-density lipoprotein (VLDL) cholesterol (mmol/L) at weeks 26, 52 and 78 is presented as ratio to baseline. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HDL Cholesterol (Ratio to Baseline)</measure>
    <time_frame>Week 0, week 26, week 52, week 78</time_frame>
    <description>Change from baseline (week 0) in high-density lipoprotein (HDL) cholesterol (mmol/L) at weeks 26, 52 and 78 is presented as ratio to baseline. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Triglycerides (Ratio to Baseline)</measure>
    <time_frame>Week 0, week 26, week 52, week 78</time_frame>
    <description>Change from baseline (week 0) in triglycerides (mmol/L) at weeks 26, 52 and 78 is presented as ratio to baseline. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Free Fatty Acids (Ratio to Baseline)</measure>
    <time_frame>Week 0, week 26, week 52, week 78</time_frame>
    <description>Change from baseline (week 0) in free fatty acids (FFA) (mmol/L) at weeks 26, 52 and 78 is presented as ratio to baseline. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product. Because of an issue with the handling of the blood samples for FFA, all FFA data were considered invalid for this trial; thus, no conclusion with regards to FFA levels can be made based on the data presented here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SMPG - Mean 7-point Profile</measure>
    <time_frame>Week 0, week 26, week 52, week 78</time_frame>
    <description>Change from baseline (week 0) in mean 7-point self-measured plasma glucose (SMPG) profile. SMPG was recorded at the following 7 time points: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after dinner and at bedtime. Mean 7-point profile was defined as the area under the profile, calculated using the trapezoidal method, divided by the measurement time. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SMPG - Mean Postprandial Increment Over All Meals</measure>
    <time_frame>Week 0, week 26, week 52, week 78</time_frame>
    <description>Change from baseline (week 0) in the average of the post-prandial increments over all meals was evaluated at weeks 26, 52 and 78. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Who Achieve HbA1c &lt;7.0% (53 mmol/Mol) ADA Target (Yes/no)</measure>
    <time_frame>Week 26, week 52, week 78</time_frame>
    <description>Participants who achieved HbA1c &lt;7.0% (American Diabetes Association (ADA) target) (yes/no), was evaluated at weeks 26, 52 and 78. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Who Achieve HbA1c ≤6.5% (48 mmol/Mol) AACE Target (Yes/no)</measure>
    <time_frame>Week 26, week 52, week 78</time_frame>
    <description>Participants who achieved HbA1c less than or equal to 6.5% (American Association of Clinical Endocrinologists (AACE) target) (yes/no) at weeks 26, 52 and 78 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Who Achieve Weight Loss ≥5% (Yes/no)</measure>
    <time_frame>Week 26, week 52, week 78</time_frame>
    <description>Participants who achieved weight loss more than or equal to 5% of their baseline body weight (yes/no) at weeks 26, 52 and 78 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Who Achieve Weight Loss ≥10% (Yes/no)</measure>
    <time_frame>Week 26, week 52, week 78</time_frame>
    <description>Participants who achieved weight loss more than or equal to 10% of their baseline body weight (yes/no) at weeks 26, 52 and 78 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Who Achieve HbA1c &lt;7.0 % (53 mmol/Mol) Without Hypoglycaemia (Severe or BG Confirmed Symptomatic Hypoglycaemia) and no Weight Gain (Yes/no)</measure>
    <time_frame>Week 26, week 52, week 78</time_frame>
    <description>Participants who achieved HbA1c less than 7.0 % without severe or blood glucose (BG) confirmed symptomatic hypoglycaemia and without weight gain (yes/no) at weeks 26, 52 and 78 are presented. Severe hypoglycaemia was defined as an episode requiring assistance of another person to actively administer carbohydrate or glucagon, or take other corrective actions. BG-confirmed symptomatic hypoglycaemia was defined as an episode with plasma glucose value &lt;3.1 mmol/L with symptoms consistent with hypoglycaemia. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Who Achieve HbA1c Reduction ≥1% (10.9 mmol/Mol) and Weight Loss ≥3% (Yes/no)</measure>
    <time_frame>Week 26, week 52, week 78</time_frame>
    <description>Participants who achieved HbA1c reduction more than or equal to 1% of their baseline HbA1c and weight loss of more than or equal to 3% of their baseline body weight (yes/no) at weeks 26, 52 and 78 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Additional Anti-diabetic Medication</measure>
    <time_frame>Weeks 0-78</time_frame>
    <description>Presented results are the number of participants who had taken additional anti-diabetic medication anytime during the periods, from week 0 to week 26, week 0 to week 52 and week 0 to week 78. Additional anti-diabetic medication was defined as any new anti-diabetic medication used for more than 21 days with the initiation at or after randomisation (week 0) and before (planned) end-of-treatment (week 78), and/or intensification of anti-diabetic medication (a more than 20% increase in dose relative to baseline) for more than 21 days with the intensification at or after randomisation and before (planned) end-of-treatment. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Rescue Medication</measure>
    <time_frame>Weeks 0-78</time_frame>
    <description>Presented results are the number of participants who had taken rescue medication anytime during the periods, from week 0 to week 26, week 0 to week 52 and week 0 to week 78. Rescue medication was defined as any new anti-diabetic medication used as add-on to trial product and used for more than 21 days with the initiation at or after randomisation (week 0) and before last day on trial product, and/or intensification of anti-diabetic medication (a more than 20% increase in dose relative to baseline) for more than 21 days with the intensification at or after randomisation and before last day on trial product. Results are based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was on treatment with trial product, excluding any period after initiation of rescue medication and/or premature trial product discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of TEAEs During Exposure to Trial Product</measure>
    <time_frame>Weeks 0-83</time_frame>
    <description>Treatment emergent adverse events (TEAEs) were recorded from week 0 to week 83 (78-week treatment period plus the 5-week follow-up period). Adverse events (AEs) with onset during the on-treatment observation period were considered treatment-emergent. On-treatment observation period: Time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Amylase (Ratio to Baseline)</measure>
    <time_frame>Week 0, week 26, week 52, week 78</time_frame>
    <description>Change from baseline (week 0) in amylase (units/litre (U/L)) at weeks 26, 52 and 78 is presented as ratio to baseline. Results are based on the data from the on-treatment observation period which was the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lipase (Ratio to Baseline)</measure>
    <time_frame>Week 0, week 26, week 52, week 78</time_frame>
    <description>Change from baseline (week 0) in lipase (U/L) at weeks 26, 52 and 78 is presented as ratio to baseline. Results are based on the data from the on-treatment observation period which was the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pulse Rate</measure>
    <time_frame>Week 0, week 26, week 52, week 78</time_frame>
    <description>Change from baseline (week 0) in pulse rate was evaluated at weeks 26, 52 and 78. Results are based on the data from the on-treatment observation period which was the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SBP and DBP</measure>
    <time_frame>Week 0, week 26, week 52, week 78</time_frame>
    <description>Change from baseline (week 0) in systolic blood pressure (SBP) and diastolic blood pressure (DBP) was evaluated at weeks 26, 52 and 78. Results are based on the data from the on-treatment observation period which was the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ECG Evaluation</measure>
    <time_frame>Week 0, week 26, week 52, week 78</time_frame>
    <description>Change from baseline (week 0) in electrocardiogram (ECG) was evaluated at weeks 26, 52 and 78. Change from baseline results are presented as shift in findings (normal, abnormal and not clinically significant (NCS) and abnormal and clinically significant (CS)) from week 0 to week 26, 52 and 78. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Examination</measure>
    <time_frame>Week -2, week 52, week 78</time_frame>
    <description>Participants with physical examination findings, normal, abnormal NCS and abnormal CS at baseline (weeks -2), weeks 52 and 78 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product. Results are presented for the following examinations: 1) Cardiovascular system; 2) Central and peripheral nervous system; 3) Gastrointestinal system, incl. mouth; 4) General appearance; 5) Head, ears, eyes, nose, throat, neck; 6) Lymph node palpation; 7) Musculoskeletal system; 8) Respiratory system; 9) Skin; 10) Thyroid gland.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Eye Examination Category</measure>
    <time_frame>Week -2, week 52, week 78</time_frame>
    <description>Participants with eye examination (fundoscopy) findings, normal, abnormal NCS and abnormal CS at baseline (week -2), week 52 and week 78 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Anti-semaglutide Binding Antibodies (Yes/no)</measure>
    <time_frame>Weeks 0-83</time_frame>
    <description>This outcome measure is only applicable for the oral semaglutide treatment arms (3 mg, 7 mg and 14 mg). Number of participants who measured with anti-semaglutide binding antibodies anytime during post-baseline visits (weeks 0-83) are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Anti-semaglutide Neutralising Antibodies (Yes/no)</measure>
    <time_frame>Weeks 0-83</time_frame>
    <description>This outcome measure is only applicable for the oral semaglutide treatment arms (3 mg, 7 mg and 14 mg). Number of participants who measured with anti-semaglutide neutralising antibodies anytime during post-baseline visits (weeks 0-83) are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Anti-semaglutide Binding Antibodies Cross Reacting With Native GLP-1 (Yes/no)</measure>
    <time_frame>Weeks 0-83</time_frame>
    <description>This outcome measure is only applicable for the oral semaglutide treatment arms (3 mg, 7 mg and 14 mg). Number of participants who measured with anti-semaglutide binding antibodies cross reacting with native glucagon-like peptide-1 (GLP-1) anytime during post-baseline visits (weeks 0-83) are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Anti-semaglutide Neutralising Antibodies Cross Reacting With Native GLP-1 (Yes/no)</measure>
    <time_frame>Weeks 0-83</time_frame>
    <description>This outcome measure is only applicable for the oral semaglutide treatment arms (3 mg, 7 mg and 14 mg). Number of participants who measured with anti-semaglutide neutralising antibodies cross reacting with native GLP-1 anytime during post-baseline visits (weeks 0-83) are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-semaglutide Binding Antibody Levels</measure>
    <time_frame>Weeks 0-83</time_frame>
    <description>This outcome measure is only applicable for the oral semaglutide treatment arms (3 mg, 7 mg and 14 mg). It is based on the data from participants who were measured with anti-semaglutide antibodies anytime during post-baseline visits (weeks 0-83). Results are presented as percentage of bound radioactivity-labelled semaglutide /total added radioactivity-labelled semaglutide (%B/T). Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Treatment-emergent Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes</measure>
    <time_frame>Weeks 0-83</time_frame>
    <description>Treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes were recorded during weeks 0-83 (78-week treatment period plus the 5-week follow-up period). Hypoglycaemic episodes with onset during the on-treatment observation period were considered treatment-emergent. On-treatment observation period was defined as the time period when a subject was on treatment with trial product, including any period after initiation of rescue medication. Severe hypoglycaemia was defined as an episode requiring assistance of another person to actively administer carbohydrate or glucagon, or take other corrective actions. BG-confirmed symptomatic hypoglycaemia: Confirmed by a glucose value &lt;3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Treatment-emergent Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes</measure>
    <time_frame>Weeks 0-83</time_frame>
    <description>Treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes were recorded from week 0 to week 83 (78-week treatment period plus the 5-week follow-up period). Hypoglycaemic episodes with onset during the on-treatment observation period were considered treatment-emergent. On-treatment observation period was defined as the time period when a subject was on treatment with trial product, including any period after initiation of rescue medication. Severe hypoglycaemia was defined as an episode requiring assistance of another person to actively administer carbohydrate or glucagon, or take other corrective actions. BG-confirmed symptomatic hypoglycaemia: Confirmed by a glucose value &lt;3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Semaglutide Plasma Concentration in a Subset of the Participants for Population PK Analyses</measure>
    <time_frame>Weeks 0-83</time_frame>
    <description>This outcome measure is only applicable for the oral semaglutide treatment arms (3 mg, 7 mg and 14 mg). Semaglutide plasma concentrations for participants in the pharmacokinetic (PK) subpopulation are presented. The PK subpopulation consisted of participants from sites in Germany, Japan and the United States receiving oral semaglutide (3 mg, 7 mg or 14 mg). Results are based on the data from the on-treatment observation period and follow-up period. The on-treatment observation period was the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SF-36v2 (Acute Version) Health Survey: Scores From the 8 Domains, the Physical Component Summary (PCS) and the Mental Component Summary (MCS)</measure>
    <time_frame>Week 0, week 26, week 52, week 78</time_frame>
    <description>SF-36 is a 36-item patient-reported survey of patient health that measures the participant's overall health-related quality of life (HRQoL). SF-36v2™ (acute version) questionnaire measured eight domains of functional health and well-being as well as two component summary scores (physical component summary (PCS) and mental component summary (MCS)). The 0-100 scale scores (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. In the metric of norm-based scores, 50 and 10 corresponds to the mean and standard deviation respectively of the 2009 U.S. general population. Change from baseline (week 0) in the domain scores and component summary (PCS and MCS) scores were evaluated at weeks 26, 52 and 78. A positive change score indicates an improvement since baseline. Results are based on the data from the in-trial observation period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IWQoL-Lite-CT: Total Score and Scores From the 4 Domains</measure>
    <time_frame>Week 0, week 26, week 52, week 78</time_frame>
    <description>The Impact of Weight on Quality of Life Clinical Trials Version (IWQOL-Lite-CT) is designed to assess the impact of changes in weight on patients' quality of life within the context of clinical trials. The items of the IWQOL-Lite-CT pertain to physical functioning (physical, physical function and pain/discomfort) and psychosocial domains and all items employ a 5-point graded response scale (never, rarely, sometimes, usually, always; or not at all true, a little true, moderately true, mostly true, completely true). All IWQOL-Lite-CT composite scores range from 0 to 100, with higher scores reflecting better levels of functioning. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CoEQ: Scores From the 4 Domains and the 19 Items</measure>
    <time_frame>Week 0, week 26, week 52, week 78</time_frame>
    <description>Change from baseline (week 0) in Control of Eating Questionnaire (CoEQ) was evaluated at weeks (wk) 26, 52 and 78. The CoEQ comprised 19 items to assess the intensity and type of food cravings, as well as subjective sensation of appetite and mood, with the 4 domains: 'craving control' (items 9-12, 19), 'positive mood' (items 5-8), 'craving for savoury' (items 4, 16-18) and 'craving for sweet' (items 3, 13-15). The 19 items were scored on an 11-point graded response scale ranging from 10 to 0, with items relating to each of the 4 domains being averaged to create a final score. A low score in the domains 'craving for sweet and 'craving for savoury' represents a low level of craving; whereas a high score in the domains 'craving control' and 'positive mood' represents good control and a good mood, respectively. Results are based on the data from the in-trial observation period.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1864</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Semaglutide 3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Semaglutide 7 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Semaglutide 14 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaglutide</intervention_name>
    <description>Oral administration once-daily</description>
    <arm_group_label>Semaglutide 14 mg</arm_group_label>
    <arm_group_label>Semaglutide 3 mg</arm_group_label>
    <arm_group_label>Semaglutide 7 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitagliptin</intervention_name>
    <description>Oral administration once-daily</description>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Oral administration once-daily</description>
    <arm_group_label>Semaglutide 14 mg</arm_group_label>
    <arm_group_label>Semaglutide 3 mg</arm_group_label>
    <arm_group_label>Semaglutide 7 mg</arm_group_label>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, age at least 18 years at the time of signing informed consent For
             Japan only: Male or female, age at least 20 years at the time of signing informed
             consent

          -  Diagnosed with T2DM (type 2 diabetes mellitus) for at least 90 days prior to day of
             screening

          -  HbA1c (glycosylated haemoglobin) 7.0-10.5 % (53-91 mmol/mol) (both inclusive).

          -  Stable daily dose of metformin (equal or above 1500 mg or maximum tolerated dose as
             documented in subject medical record) alone or in combination with SU (= half of the
             maximum approved dose according to local label or maximum tolerated dose as documented
             in subject medical record) within 90 days prior to the day of screening

        Exclusion Criteria:

          -  Female who is pregnant, breast-feeding or intends to become pregnant or is of
             child-bearing potential and not using adequate contraceptive methods (adequate
             contraceptive measures as required by local regulation or practice). For certain
             specific countries: Additional specific requirements apply

          -  Family or personal history of Multiple Endocrine Neoplasia Type 2 (MEN 2) or Medullary
             Thyroid Carcinoma (MTC)

          -  History of pancreatitis (acute or chronic)

          -  History of major surgical procedures involving the stomach potentially affecting
             absorption of trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy,
             gastric bypass surgery)

          -  Any of the following: myocardial infarction, stroke or hospitalization for unstable
             angina and/or transient ischaemic attack within the past 180 days prior to the day of
             screening

          -  Subjects presently classified as being in New York Heart Association (NYHA) Class IV.

          -  Planned coronary, carotid or peripheral artery revascularisation known on the day of
             screening.

          -  Renal impairment defined as estimated Glomerular Filtration Rate (eGFR) below 60
             mL/min/1.73 m^2 as per Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)

          -  History or presence of malignant neoplasms within the last 5 years (except basal and
             squamous cell skin cancer and in-situ carcinomas)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tuscumbia</city>
        <state>Alabama</state>
        <zip>35674</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <zip>95608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Spring Hill</city>
        <state>Florida</state>
        <zip>34609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Perry</city>
        <state>Georgia</state>
        <zip>31069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83646</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Gurnee</city>
        <state>Illinois</state>
        <zip>60031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Avon</city>
        <state>Indiana</state>
        <zip>46123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Park City</city>
        <state>Kansas</state>
        <zip>67219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Natchitoches</city>
        <state>Louisiana</state>
        <zip>71457-5881</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sterling Heights</city>
        <state>Michigan</state>
        <zip>48310-3503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jefferson City</city>
        <state>Missouri</state>
        <zip>65109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701-1652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Trenton</city>
        <state>New Jersey</state>
        <zip>08611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>New Windsor</city>
        <state>New York</state>
        <zip>12553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>West Seneca</city>
        <state>New York</state>
        <zip>14224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28625</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Whiteville</city>
        <state>North Carolina</state>
        <zip>28472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Franklin</city>
        <state>Ohio</state>
        <zip>45005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Maumee</city>
        <state>Ohio</state>
        <zip>43537</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Corvallis</city>
        <state>Oregon</state>
        <zip>97330-3737</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jersey Shore</city>
        <state>Pennsylvania</state>
        <zip>17740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>McMurray</city>
        <state>Pennsylvania</state>
        <zip>15317</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <zip>29341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pelzer</city>
        <state>South Carolina</state>
        <zip>29669</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Summerville</city>
        <state>South Carolina</state>
        <zip>29485</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620-7352</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Humboldt</city>
        <state>Tennessee</state>
        <zip>38343</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>South Burlington</city>
        <state>Vermont</state>
        <zip>05403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <zip>98502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Caba</city>
        <zip>1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Caba</city>
        <zip>C1179AAB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <zip>C1056ABJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cordoba</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Córdoba</city>
        <zip>5008</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>01228-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Chalons-en-Champagne Cedex</city>
        <zip>51005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>DIJON cedex</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>LA ROCHE-sur-YON cedex 9</city>
        <zip>85295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>LA ROCHELLE cedex</city>
        <zip>17019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Le Creusot</city>
        <zip>71200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Marseille</city>
        <zip>13006</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nanterre</city>
        <zip>92014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nantes Cedex 01</city>
        <zip>448093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nantes</city>
        <zip>44200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Narbonne</city>
        <zip>11108</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>PERPIGNAN cedex</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Périgueux</city>
        <zip>24019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Venissieux</city>
        <zip>69200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bad Mergentheim</city>
        <zip>97980</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12163</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Elsterwerda</city>
        <zip>04910</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Essen</city>
        <zip>45219</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Falkensee</city>
        <zip>14612</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Friedrichsthal</city>
        <zip>66299</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22607</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Münster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Saint Ingbert-Oberwürzbach</city>
        <zip>66386</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Stuttgart</city>
        <zip>70378</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500072</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Gurgaon</city>
        <state>Haryana</state>
        <zip>122001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>4000016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411040</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>New Dehli</city>
        <state>New Delhi</state>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bhubaneshwar</city>
        <state>Orissa</state>
        <zip>751003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Chandigarh</city>
        <state>Punjab</state>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600 013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600086</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Vellore</city>
        <state>Tamil Nadu</state>
        <zip>632004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700064</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kfar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Petah-Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ra'anana</city>
        <zip>43452</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6937947</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Asahikawa-shi, Hokkaido</city>
        <zip>070-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Gunma</city>
        <zip>373-0036</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>060-0062</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ibaraki</city>
        <zip>311-0113</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Iruma-shi, Saitama</city>
        <zip>358-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kanagawa</city>
        <zip>235-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kashiwara-shi, Osaka</city>
        <zip>582-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kyoto-shi, Kyoto</city>
        <zip>601-1495</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kyoto-shi, Kyoto</city>
        <zip>615-0035</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Miyazaki</city>
        <zip>880-0034</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>569-1045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Shinjuku-ku, Tokyo</city>
        <zip>162-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Shizuoka-shi, Shizuoka</city>
        <zip>424-0853</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>103-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>103-0028</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Toluca</city>
        <state>Estado De México</state>
        <zip>50130</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44670</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ciudad Madero</city>
        <state>Tamaulipas</state>
        <zip>89440</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pitesti</city>
        <state>Arges</state>
        <zip>110084</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Oradea</city>
        <state>Bihor</state>
        <zip>410025</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Craiova</city>
        <state>Dolj</state>
        <zip>200642</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Baia Mare</city>
        <state>Maramures</state>
        <zip>430222</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Targu Mures</city>
        <state>Mures</state>
        <zip>540098</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ploiesti</city>
        <state>Prahova</state>
        <zip>100342</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Timisoara</city>
        <state>Timis</state>
        <zip>300125</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>020359</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>020475</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Iasi</city>
        <zip>700111</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Iasi</city>
        <zip>700469</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Satu Mare</city>
        <zip>440055</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Timisoara</city>
        <zip>300736</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Barnaul</city>
        <zip>656045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>117036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>119435</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Penza</city>
        <zip>440026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tomsk</city>
        <zip>634041</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tomsk</city>
        <zip>634050</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Port Elizabeth</city>
        <state>Eastern Cape</state>
        <zip>6045</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bloemfontein</city>
        <state>Free State</state>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>1818</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>1829</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2198</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Krugersdorp</city>
        <state>Gauteng</state>
        <zip>1739</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <zip>4120</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <zip>0101</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34371</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34718</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34722</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>İstanbul</city>
        <zip>34752</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34890</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Samsun</city>
        <zip>55139</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cherkasy</city>
        <zip>18009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <zip>04114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mykolaiv</city>
        <zip>54003</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Odesa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ternopil</city>
        <zip>46002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Zaporizhia</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Zhytomyr</city>
        <zip>10002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Basingstoke</city>
        <zip>RG24 9GT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cardiff</city>
        <zip>CF5 4AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Chester</city>
        <zip>CH2 1UL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Crewe</city>
        <zip>CW5 5NX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Doncaster</city>
        <zip>DN9 2HY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Leicester</city>
        <zip>LE5 4PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Preston</city>
        <zip>PR2 9HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rotherham</city>
        <zip>S651DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sidcup</city>
        <zip>DA14 6LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Soham</city>
        <zip>CB7 5JD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Swansea</city>
        <zip>SA2 8PP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Taunton</city>
        <zip>TA1 5DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Torquay</city>
        <zip>TQ2 7AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Wellingborough</city>
        <zip>NN8 4RW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Mexico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Rosenstock J, Allison D, Birkenfeld AL, Blicher TM, Deenadayalan S, Jacobsen JB, Serusclat P, Violante R, Watada H, Davies M; PIONEER 3 Investigators. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. JAMA. 2019 Apr 16;321(15):1466-1480. doi: 10.1001/jama.2019.2942.</citation>
    <PMID>30903796</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 10, 2015</study_first_submitted>
  <study_first_submitted_qc>November 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2015</study_first_posted>
  <results_first_submitted>October 15, 2019</results_first_submitted>
  <results_first_submitted_qc>February 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 27, 2020</results_first_posted>
  <disposition_first_submitted>February 1, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>February 1, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 5, 2018</disposition_first_posted>
  <last_update_submitted>February 14, 2020</last_update_submitted>
  <last_update_submitted_qc>February 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 21, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT02607865/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 21, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT02607865/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The trial was conducted at 200 sites in 14 countries: Argentina-5, Brazil-1, France-10, Germany-12, Israel-8, Japan-16, Mexico-5, Romania-12, Russian Federation-8, South Africa-11, Turkey-7, Ukraine-8, United Kingdom (UK)-14, United States (US)-83. In addition, 6 sites screened, but didn’t randomise any subjects: France-1, Turkey-1, UK-1 and US-3.</recruitment_details>
      <pre_assignment_details>Data presented in “participant flow” is based on the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Oral Semaglutide 3 mg</title>
          <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
        </group>
        <group group_id="P2">
          <title>Oral Semaglutide 7 mg</title>
          <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
        </group>
        <group group_id="P3">
          <title>Oral Semaglutide 14 mg</title>
          <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
        </group>
        <group group_id="P4">
          <title>Sitagliptin 100 mg</title>
          <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="466"/>
                <participants group_id="P2" count="466"/>
                <participants group_id="P3" count="465"/>
                <participants group_id="P4" count="467"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set (FAS)</title>
              <participants_list>
                <participants group_id="P1" count="466"/>
                <participants group_id="P2" count="465"/>
                <participants group_id="P3" count="465"/>
                <participants group_id="P4" count="467"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis Set (SAS)</title>
              <participants_list>
                <participants group_id="P1" count="466"/>
                <participants group_id="P2" count="464"/>
                <participants group_id="P3" count="465"/>
                <participants group_id="P4" count="466"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="433"/>
                <participants group_id="P2" count="436"/>
                <participants group_id="P3" count="438"/>
                <participants group_id="P4" count="451"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unclassified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The FAS comprised all randomised participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Oral Semaglutide 3 mg</title>
          <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
        </group>
        <group group_id="B2">
          <title>Oral Semaglutide 7 mg</title>
          <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
        </group>
        <group group_id="B3">
          <title>Oral Semaglutide 14 mg</title>
          <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
        </group>
        <group group_id="B4">
          <title>Sitagliptin 100 mg</title>
          <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="466"/>
            <count group_id="B2" value="465"/>
            <count group_id="B3" value="465"/>
            <count group_id="B4" value="467"/>
            <count group_id="B5" value="1863"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="10"/>
                    <measurement group_id="B2" value="58" spread="10"/>
                    <measurement group_id="B3" value="57" spread="10"/>
                    <measurement group_id="B4" value="58" spread="10"/>
                    <measurement group_id="B5" value="58" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                    <measurement group_id="B2" value="220"/>
                    <measurement group_id="B3" value="218"/>
                    <measurement group_id="B4" value="229"/>
                    <measurement group_id="B5" value="879"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="254"/>
                    <measurement group_id="B2" value="245"/>
                    <measurement group_id="B3" value="247"/>
                    <measurement group_id="B4" value="238"/>
                    <measurement group_id="B5" value="984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Race was recorded as 'Not Applicable' for Brazil and France.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="344"/>
                    <measurement group_id="B2" value="330"/>
                    <measurement group_id="B3" value="317"/>
                    <measurement group_id="B4" value="333"/>
                    <measurement group_id="B5" value="1324"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="160"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="59"/>
                    <measurement group_id="B5" value="245"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not applicable</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Ethnicity was recorded as 'Not Applicable' for France.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="93"/>
                    <measurement group_id="B5" value="321"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="385"/>
                    <measurement group_id="B2" value="378"/>
                    <measurement group_id="B3" value="377"/>
                    <measurement group_id="B4" value="366"/>
                    <measurement group_id="B5" value="1506"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not applicable</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycosylated haemoglobin (HbA1c)</title>
          <units>Percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.3" spread="1.0"/>
                    <measurement group_id="B2" value="8.4" spread="1.0"/>
                    <measurement group_id="B3" value="8.3" spread="0.9"/>
                    <measurement group_id="B4" value="8.3" spread="0.9"/>
                    <measurement group_id="B5" value="8.3" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in HbA1c: Week 26</title>
        <description>Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated at week 26. The endpoint was evaluated based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product. The endpoint was also evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was on treatment with trial product, excluding any period after initiation of rescue medication and/or premature trial product discontinuation.</description>
        <time_frame>Week 0, week 26</time_frame>
        <population>Overall number of participants analyzed = full analysis set (FAS) which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1c: Week 26</title>
          <description>Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated at week 26. The endpoint was evaluated based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product. The endpoint was also evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was on treatment with trial product, excluding any period after initiation of rescue medication and/or premature trial product discontinuation.</description>
          <population>Overall number of participants analyzed = full analysis set (FAS) which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
          <units>Percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="465"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>In-trial</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="435"/>
                    <count group_id="O2" value="438"/>
                    <count group_id="O3" value="436"/>
                    <count group_id="O4" value="446"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="1.0"/>
                    <measurement group_id="O2" value="-1.1" spread="1.1"/>
                    <measurement group_id="O3" value="-1.3" spread="1.0"/>
                    <measurement group_id="O4" value="-0.8" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>On-treatment without rescue medication</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="391"/>
                    <count group_id="O2" value="409"/>
                    <count group_id="O3" value="398"/>
                    <count group_id="O4" value="419"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="1.0"/>
                    <measurement group_id="O2" value="-1.2" spread="1.1"/>
                    <measurement group_id="O3" value="-1.4" spread="1.0"/>
                    <measurement group_id="O4" value="-0.8" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was based on a pattern mixture model using multiple imputation to handle missing week 26 data, assuming that data were missing at random within the groups used for imputation. The imputed data sets were analysed using an analysis of covariance (ANCOVA) model with treatment, strata, and region as categorical fixed effects and baseline HbA1c value as covariate for each of the 1000 imputed complete data sets, and pooled by Rubin's rule to draw inference.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>This hypothesis was controlled for multiplicity. Results are based on the data from the in-trial observation period. The estimated treatment effect includes the effect of any rescue medication and any effect after premature trial product discontinuation (treatment policy estimand). A value of 0.3% (the non-inferiority margin) was added to imputed values at week 26 for the oral semaglutide treatment arm only.</non_inferiority_desc>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Unadjusted two-sided p-value for test of no difference from the non-inferiority margin (non-inferiority). The non-inferiority margin was 0.3%.</p_value_desc>
            <method>Pattern mixture model</method>
            <param_type>Mean treatment difference</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
            <estimate_desc>Oral semaglutide 14 mg - Sitagliptin 100 mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was based on a pattern mixture model using multiple imputation to handle missing week 26 data, assuming that data were missing at random within the groups used for imputation. The imputed data sets were analysed using an ANCOVA model with treatment, strata, and region as categorical fixed effects and baseline HbA1c value as covariate for each of the 1000 imputed complete data sets, and pooled by Rubin's rule to draw inference.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This hypothesis was controlled for multiplicity. Results are based on the data from the in-trial observation period. The estimated treatment effect includes the effect of any rescue medication and any effect after premature trial product discontinuation (treatment policy estimand).</non_inferiority_desc>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Unadjusted two-sided p-value for test of no difference from 0 (superiority).</p_value_desc>
            <method>Pattern mixture model</method>
            <param_type>Mean treatment difference</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
            <estimate_desc>Oral semaglutide 14 mg - Sitagliptin 100 mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was based on a pattern mixture model using multiple imputation to handle missing week 26 data, assuming that data were missing at random within the groups used for imputation. The imputed data sets were analysed using an ANCOVA model with treatment, strata, and region as categorical fixed effects and baseline HbA1c value as covariate for each of the 1000 imputed complete data sets, and pooled by Rubin's rule to draw inference.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>This hypothesis was controlled for multiplicity. Results are based on the data from the in-trial observation period. The estimated treatment effect includes the effect of any rescue medication and any effect after premature trial product discontinuation (treatment policy estimand). A value of 0.3% (the non-inferiority margin) was added to imputed values at week 26 for the oral semaglutide treatment arm only.</non_inferiority_desc>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Unadjusted two-sided p-value for test of no difference from the non-inferiority margin (non-inferiority). The non-inferiority margin was 0.3%.</p_value_desc>
            <method>Pattern mixture model</method>
            <param_type>Mean treatment difference</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
            <estimate_desc>Oral semaglutide 7 mg - Sitagliptin 100 mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was based on a pattern mixture model using multiple imputation to handle missing week 26 data, assuming that data were missing at random within the groups used for imputation. The imputed data sets were analysed using an ANCOVA model with treatment, strata, and region as categorical fixed effects and baseline HbA1c value as covariate for each of the 1000 imputed complete data sets, and pooled by Rubin's rule to draw inference.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This hypothesis was controlled for multiplicity. Results are based on the data from the in-trial observation period. The estimated treatment effect includes the effect of any rescue medication and any effect after premature trial product discontinuation (treatment policy estimand).</non_inferiority_desc>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Unadjusted two-sided p-value for test of no difference from 0 (superiority).</p_value_desc>
            <method>Pattern mixture model</method>
            <param_type>Mean treatment difference</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
            <estimate_desc>Oral semaglutide 7 mg - Sitagliptin 100 mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was based on a pattern mixture model using multiple imputation to handle missing week 26 data, assuming that data were missing at random within the groups used for imputation. The imputed data sets were analysed using an ANCOVA model with treatment, strata, and region as categorical fixed effects and baseline HbA1c value as covariate for each of the 1000 imputed complete data sets, and pooled by Rubin's rule to draw inference.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>This hypothesis was controlled for multiplicity. Results are based on the data from the in-trial observation period. The estimated treatment effect includes the effect of any rescue medication and any effect after premature trial product discontinuation (treatment policy estimand). A value of 0.3% (the non-inferiority margin) was added to imputed values at week 26 for the oral semaglutide treatment arm only.</non_inferiority_desc>
            <p_value>= 0.0856</p_value>
            <p_value_desc>Unadjusted two-sided p-value for test of no difference from the non-inferiority margin (non-inferiority). The non-inferiority margin was 0.3%.</p_value_desc>
            <method>Pattern mixture model</method>
            <param_type>Mean treatment difference</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
            <estimate_desc>Oral semaglutide 3 mg - Sitagliptin 100 mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was based on a pattern mixture model using multiple imputation to handle missing week 26 data, assuming that data were missing at random within the groups used for imputation. The imputed data sets were analysed using an ANCOVA model with treatment, strata, and region as categorical fixed effects and baseline HbA1c value as covariate for each of the 1000 imputed complete data sets, and pooled by Rubin's rule to draw inference.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This hypothesis was not controlled for multiplicity, since the non-inferiority test of change in HbA1c for oral semaglutide 3 mg versus sitagliptin 100 mg could not be confirmed. Results are based on the data from the in-trial observation period. The estimated treatment effect includes the effect of any rescue medication and any effect after premature trial product discontinuation (treatment policy estimand).</non_inferiority_desc>
            <p_value>= 0.0080</p_value>
            <p_value_desc>Unadjusted two-sided p-value for test of no difference from 0 (superiority).</p_value_desc>
            <method>Pattern mixture model</method>
            <param_type>Mean treatment difference</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
            <estimate_desc>Oral semaglutide 3 mg - Sitagliptin 100 mg. If the mean treatment difference is non-negative, the superiority hypothesis of oral semaglutide 3 mg vs sitagliptin 100 mg will never be confirmed irrespective of the observed two-sided p-value.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was based on a mixed model for repeated measurements (MMRM) that assumed data to be missing at random. As dependent variables, the MMRM model included all post-baseline values collected at scheduled visits up to and including week 26. The independent effects were treatment, strata and region as categorical fixed effects and the baseline HbA1c value as a covariate, all nested within visit, and an unstructured residual covariance matrix.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>This hypothesis was not controlled for multiplicity. Results are based on the data from the on-treatment without rescue medication observation period. The estimated treatment effect excludes the effect of any rescue medication and any effect after premature trial product discontinuation (hypothetical estimand).</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Unadjusted two-sided p-value for test of no difference from the non-inferiority margin (non-inferiority). The non-inferiority margin was 0.3%.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean treatment difference</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>-0.5</ci_upper_limit>
            <estimate_desc>Oral semaglutide 14 mg - Sitagliptin 100 mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was based on a MMRM that assumed data to be missing at random. As dependent variables, the MMRM model included all post-baseline values collected at scheduled visits up to and including week 26. The independent effects were treatment, strata and region as categorical fixed effects and the baseline HbA1c value as a covariate, all nested within visit, and an unstructured residual covariance matrix.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This hypothesis was not controlled for multiplicity. Results are based on the data from the on-treatment without rescue medication observation period. The estimated treatment effect excludes the effect of any rescue medication and any effect after premature trial product discontinuation (hypothetical estimand).</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Unadjusted two-sided p-value for test of no difference from 0 (superiority).</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean treatment difference</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>-0.5</ci_upper_limit>
            <estimate_desc>Oral semaglutide 14 mg - Sitagliptin 100 mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was based on a MMRM that assumed data to be missing at random. As dependent variables, the MMRM model included all post-baseline values collected at scheduled visits up to and including week 26. The independent effects were treatment, strata and region as categorical fixed effects and the baseline HbA1c value as a covariate, all nested within visit, and an unstructured residual covariance matrix.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>This hypothesis was not controlled for multiplicity. Results are based on the data from the on-treatment without rescue medication observation period. The estimated treatment effect excludes the effect of any rescue medication and any effect after premature trial product discontinuation (hypothetical estimand).</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Unadjusted two-sided p-value for test of no difference from the non-inferiority margin (non-inferiority). The non-inferiority margin was 0.3%.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean treatment difference</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
            <estimate_desc>Oral semaglutide 7 mg - Sitagliptin 100 mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was based on a MMRM that assumed data to be missing at random. As dependent variables, the MMRM model included all post-baseline values collected at scheduled visits up to and including week 26. The independent effects were treatment, strata and region as categorical fixed effects and the baseline HbA1c value as a covariate, all nested within visit, and an unstructured residual covariance matrix.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This hypothesis was not controlled for multiplicity. Results are based on the data from the on-treatment without rescue medication observation period. The estimated treatment effect excludes the effect of any rescue medication and any effect after premature trial product discontinuation (hypothetical estimand).</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Unadjusted two-sided p-value for test of no difference from 0 (superiority).</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean treatment difference</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
            <estimate_desc>Oral semaglutide 7 mg - Sitagliptin 100 mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was based on a MMRM that assumed data to be missing at random. As dependent variables, the MMRM model included all post-baseline values collected at scheduled visits up to and including week 26. The independent effects were treatment, strata and region as categorical fixed effects and the baseline HbA1c value as a covariate, all nested within visit, and an unstructured residual covariance matrix.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>This hypothesis was not controlled for multiplicity. Results are based on the data from the on-treatment without rescue medication observation period. The estimated treatment effect excludes the effect of any rescue medication and any effect after premature trial product discontinuation (hypothetical estimand).</non_inferiority_desc>
            <p_value>=0.3851</p_value>
            <p_value_desc>Unadjusted two-sided p-value for test of no difference from the non-inferiority margin (non-inferiority). The non-inferiority margin was 0.3%.</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean treatment difference</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
            <estimate_desc>Oral semaglutide 3 mg - Sitagliptin 100 mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was based on a MMRM that assumed data to be missing at random. As dependent variables, the MMRM model included all post-baseline values collected at scheduled visits up to and including week 26. The independent effects were treatment, strata and region as categorical fixed effects and the baseline HbA1c value as a covariate, all nested within visit, and an unstructured residual covariance matrix.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>This hypothesis was not controlled for multiplicity. Results are based on the data from the on-treatment without rescue medication observation period. The estimated treatment effect excludes the effect of any rescue medication and any effect after premature trial product discontinuation (hypothetical estimand).</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Unadjusted two-sided p-value for test of no difference from 0 (superiority).</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean treatment difference</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
            <estimate_desc>Oral semaglutide 3 mg - Sitagliptin 100 mg. If the mean treatment difference is non-negative, the superiority hypothesis of oral semaglutide 3 mg vs sitagliptin 100 mg will never be confirmed irrespective of the observed two-sided p-value.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight: Week 26</title>
        <description>Change from baseline (week 0) in body weight was evaluated at week 26. The endpoint was evaluated based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product. The endpoint was also evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was on treatment with trial product, excluding any period after initiation of rescue medication and/or premature trial product discontinuation.</description>
        <time_frame>Week 0, week 26</time_frame>
        <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight: Week 26</title>
          <description>Change from baseline (week 0) in body weight was evaluated at week 26. The endpoint was evaluated based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product. The endpoint was also evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was on treatment with trial product, excluding any period after initiation of rescue medication and/or premature trial product discontinuation.</description>
          <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
          <units>Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="465"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>In-trial</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="440"/>
                    <count group_id="O3" value="439"/>
                    <count group_id="O4" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="3.2"/>
                    <measurement group_id="O2" value="-2.2" spread="3.9"/>
                    <measurement group_id="O3" value="-3.1" spread="3.8"/>
                    <measurement group_id="O4" value="-0.6" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>on-treatment without rescue medication</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="394"/>
                    <count group_id="O2" value="411"/>
                    <count group_id="O3" value="401"/>
                    <count group_id="O4" value="420"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="3.3"/>
                    <measurement group_id="O2" value="-2.2" spread="4.0"/>
                    <measurement group_id="O3" value="-3.2" spread="3.8"/>
                    <measurement group_id="O4" value="-0.6" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was based on a pattern mixture model using multiple imputation to handle missing week 26 data, assuming that data were missing at random within the groups used for imputation. The imputed data sets were analysed using an ANCOVA model with treatment, strata, and region as categorical fixed effects and baseline body weight value as covariate for each of the 1000 imputed complete data sets, and pooled by Rubin's rule to draw inference.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This hypothesis was controlled for multiplicity. Results are based on the data from the in-trial observation period. The estimated treatment effect includes the effect of any rescue medication and any effect after premature trial product discontinuation (treatment policy estimand).</non_inferiority_desc>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Unadjusted two-sided p-value for test of no difference from 0 (superiority).</p_value_desc>
            <method>Pattern mixture model</method>
            <param_type>Mean treatment difference</param_type>
            <param_value>-2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.0</ci_lower_limit>
            <ci_upper_limit>-2.0</ci_upper_limit>
            <estimate_desc>Oral semaglutide 14 mg - Sitagliptin 100 mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was based on a pattern mixture model using multiple imputation to handle missing week 26 data, assuming that data were missing at random within the groups used for imputation. The imputed data sets were analysed using an ANCOVA model with treatment, strata, and region as categorical fixed effects and baseline body weight value as covariate for each of the 1000 imputed complete data sets, and pooled by Rubin's rule to draw inference.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This hypothesis was controlled for multiplicity. Results are based on the data from the in-trial observation period. The estimated treatment effect includes the effect of any rescue medication and any effect after premature trial product discontinuation (treatment policy estimand).</non_inferiority_desc>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Unadjusted two-sided p-value for test of no difference from 0 (superiority).</p_value_desc>
            <method>Pattern mixture model</method>
            <param_type>Mean treatment difference</param_type>
            <param_value>-1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>-1.1</ci_upper_limit>
            <estimate_desc>Oral semaglutide 7 mg - Sitagliptin 100 mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was based on a pattern mixture model using multiple imputation to handle missing week 26 data, assuming that data were missing at random within the groups used for imputation. The imputed data sets were analysed using an ANCOVA model with treatment, strata, and region as categorical fixed effects and baseline body weight value as covariate for each of the 1000 imputed complete data sets, and pooled by Rubin's rule to draw inference.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This hypothesis was not controlled for multiplicity, since the non-inferiority test of change in HbA1c for oral semaglutide 3 mg versus sitagliptin 100 mg could not be confirmed. Results are based on the data from the in-trial observation period. The estimated treatment effect includes the effect of any rescue medication and any effect after premature trial product discontinuation (treatment policy estimand).</non_inferiority_desc>
            <p_value>= 0.0185</p_value>
            <p_value_desc>Unadjusted two-sided p-value for test of no difference from 0 (superiority).</p_value_desc>
            <method>Pattern mixture model</method>
            <param_type>Mean treatment difference</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
            <estimate_desc>Oral semaglutide 3 mg - Sitagliptin 100 mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was based on a MMRM that assumed data to be missing at random. As dependent variables, the MMRM model included all post-baseline values collected at scheduled visits up to and including week 26. The independent effects were treatment, strata and region as categorical fixed effects and the baseline body weight value as a covariate, all nested within visit, and an unstructured residual covariance matrix.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This hypothesis was not controlled for multiplicity. Results are based on the data from the on-treatment without rescue medication observation period. The estimated treatment effect excludes the effect of any rescue medication and any effect after premature trial product discontinuation (hypothetical estimand).</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Unadjusted two-sided p-value for test of no difference from 0 (superiority).</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean treatment difference</param_type>
            <param_value>-2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>-2.1</ci_upper_limit>
            <estimate_desc>Oral semaglutide 14 mg - Sitagliptin 100 mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was based on a MMRM that assumed data to be missing at random. As dependent variables, the MMRM model included all post-baseline values collected at scheduled visits up to and including week 26. The independent effects were treatment, strata and region as categorical fixed effects and the baseline body weight value as a covariate, all nested within visit, and an unstructured residual covariance matrix.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This hypothesis was not controlled for multiplicity. Results are based on the data from the on-treatment without rescue medication observation period. The estimated treatment effect excludes the effect of any rescue medication and any effect after premature trial product discontinuation (hypothetical estimand).</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Unadjusted two-sided p-value for test of no difference from 0 (superiority).</p_value_desc>
            <method>MMRM</method>
            <param_type>Mean treatment difference</param_type>
            <param_value>-1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>-1.1</ci_upper_limit>
            <estimate_desc>Oral semaglutide 7 mg - Sitagliptin 100 mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was based on a MMRM that assumed data to be missing at random. As dependent variables, the MMRM model included all post-baseline values collected at scheduled visits up to and including week 26. The independent effects were treatment, strata and region as categorical fixed effects and the baseline body weight value as a covariate, all nested within visit, and an unstructured residual covariance matrix.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This hypothesis was not controlled for multiplicity. Results are based on the data from the on-treatment without rescue medication observation period. The estimated treatment effect excludes the effect of any rescue medication and any effect after premature trial product discontinuation (hypothetical estimand).</non_inferiority_desc>
            <p_value>=0.0257</p_value>
            <p_value_desc>Unadjusted two-sided p-value for test of no difference from 0 (superiority).</p_value_desc>
            <method>MMRM</method>
            <param_type>type Mean treatment difference</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
            <estimate_desc>Oral semaglutide 3 mg - Sitagliptin 100 mg</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HbA1c: Weeks 52 and 78</title>
        <description>Change from baseline (week 0) in HbA1c was evaluated at weeks 52 and 78. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
        <time_frame>Week 0, week 52, week 78</time_frame>
        <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1c: Weeks 52 and 78</title>
          <description>Change from baseline (week 0) in HbA1c was evaluated at weeks 52 and 78. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
          <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
          <units>Percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="465"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="427"/>
                    <count group_id="O2" value="431"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="436"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="1.1"/>
                    <measurement group_id="O2" value="-1.0" spread="1.2"/>
                    <measurement group_id="O3" value="-1.2" spread="1.1"/>
                    <measurement group_id="O4" value="-0.7" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="421"/>
                    <count group_id="O2" value="424"/>
                    <count group_id="O3" value="425"/>
                    <count group_id="O4" value="439"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="1.1"/>
                    <measurement group_id="O2" value="-0.9" spread="1.3"/>
                    <measurement group_id="O3" value="-1.1" spread="1.1"/>
                    <measurement group_id="O4" value="-0.7" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight (kg): Weeks 52 and 78</title>
        <description>Change from baseline (week 0) in body weight was evaluated at weeks 52 and 78. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
        <time_frame>Week 0, week 52, week 78</time_frame>
        <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight (kg): Weeks 52 and 78</title>
          <description>Change from baseline (week 0) in body weight was evaluated at weeks 52 and 78. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
          <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
          <units>Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="465"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="433"/>
                    <count group_id="O3" value="435"/>
                    <count group_id="O4" value="437"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="4.1"/>
                    <measurement group_id="O2" value="-2.5" spread="4.9"/>
                    <measurement group_id="O3" value="-3.5" spread="4.7"/>
                    <measurement group_id="O4" value="-0.7" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="425"/>
                    <count group_id="O3" value="428"/>
                    <count group_id="O4" value="443"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="4.9"/>
                    <measurement group_id="O2" value="-2.8" spread="5.4"/>
                    <measurement group_id="O3" value="-3.2" spread="4.9"/>
                    <measurement group_id="O4" value="-1.0" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight (%)</title>
        <description>Relative change from baseline (week 0) in body weight (kg) was evaluated at weeks 26, 52 and 78. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
        <time_frame>Week 0, week 26, week 52, week 78</time_frame>
        <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight (%)</title>
          <description>Relative change from baseline (week 0) in body weight (kg) was evaluated at weeks 26, 52 and 78. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
          <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
          <units>Percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="465"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="440"/>
                    <count group_id="O3" value="439"/>
                    <count group_id="O4" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.23" spread="3.57"/>
                    <measurement group_id="O2" value="-2.36" spread="4.09"/>
                    <measurement group_id="O3" value="-3.44" spread="4.21"/>
                    <measurement group_id="O4" value="-0.64" spread="3.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="433"/>
                    <count group_id="O3" value="435"/>
                    <count group_id="O4" value="437"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.65" spread="4.28"/>
                    <measurement group_id="O2" value="-2.63" spread="5.09"/>
                    <measurement group_id="O3" value="-3.83" spread="5.14"/>
                    <measurement group_id="O4" value="-0.76" spread="3.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="425"/>
                    <count group_id="O3" value="428"/>
                    <count group_id="O4" value="443"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.87" spread="4.87"/>
                    <measurement group_id="O2" value="-2.92" spread="5.67"/>
                    <measurement group_id="O3" value="-3.47" spread="5.34"/>
                    <measurement group_id="O4" value="-0.99" spread="4.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in FPG</title>
        <description>Change from baseline (week 0) in fasting plasma glucose (FPG) was evaluated at weeks 26, 52 and 78. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
        <time_frame>Week 0, week 26, week 52, week 78</time_frame>
        <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in FPG</title>
          <description>Change from baseline (week 0) in fasting plasma glucose (FPG) was evaluated at weeks 26, 52 and 78. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
          <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="465"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="433"/>
                    <count group_id="O2" value="436"/>
                    <count group_id="O3" value="433"/>
                    <count group_id="O4" value="443"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="2.69"/>
                    <measurement group_id="O2" value="-1.17" spread="2.54"/>
                    <measurement group_id="O3" value="-1.67" spread="2.60"/>
                    <measurement group_id="O4" value="-0.90" spread="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="419"/>
                    <count group_id="O2" value="429"/>
                    <count group_id="O3" value="432"/>
                    <count group_id="O4" value="433"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.98" spread="2.78"/>
                    <measurement group_id="O2" value="-1.28" spread="2.62"/>
                    <measurement group_id="O3" value="-1.75" spread="2.57"/>
                    <measurement group_id="O4" value="-1.03" spread="2.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="418"/>
                    <count group_id="O2" value="419"/>
                    <count group_id="O3" value="419"/>
                    <count group_id="O4" value="434"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.07" spread="3.21"/>
                    <measurement group_id="O2" value="-1.11" spread="2.92"/>
                    <measurement group_id="O3" value="-1.65" spread="2.71"/>
                    <measurement group_id="O4" value="-0.91" spread="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in BMI</title>
        <description>Change from baseline (week 0) in body mass index (BMI) was evaluated at weeks 26, 52 and 78. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
        <time_frame>Week 0, week 26, week 52, week 78</time_frame>
        <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in BMI</title>
          <description>Change from baseline (week 0) in body mass index (BMI) was evaluated at weeks 26, 52 and 78. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
          <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
          <units>Kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="465"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="440"/>
                    <count group_id="O3" value="439"/>
                    <count group_id="O4" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.2"/>
                    <measurement group_id="O2" value="-0.8" spread="1.4"/>
                    <measurement group_id="O3" value="-1.1" spread="1.4"/>
                    <measurement group_id="O4" value="-0.2" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="433"/>
                    <count group_id="O3" value="435"/>
                    <count group_id="O4" value="437"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="1.5"/>
                    <measurement group_id="O2" value="-0.9" spread="1.7"/>
                    <measurement group_id="O3" value="-1.2" spread="1.7"/>
                    <measurement group_id="O4" value="-0.3" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="425"/>
                    <count group_id="O3" value="428"/>
                    <count group_id="O4" value="443"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="1.8"/>
                    <measurement group_id="O2" value="-1.0" spread="1.9"/>
                    <measurement group_id="O3" value="-1.1" spread="1.7"/>
                    <measurement group_id="O4" value="-0.4" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Waist Circumference</title>
        <description>Change from baseline (week 0) in waist circumference was evaluated at weeks 26, 52 and 78. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
        <time_frame>Week 0, week 26, week 52, week 78</time_frame>
        <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Waist Circumference</title>
          <description>Change from baseline (week 0) in waist circumference was evaluated at weeks 26, 52 and 78. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
          <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="465"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="439"/>
                    <count group_id="O3" value="438"/>
                    <count group_id="O4" value="445"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="5.0"/>
                    <measurement group_id="O2" value="-1.8" spread="5.2"/>
                    <measurement group_id="O3" value="-2.3" spread="5.2"/>
                    <measurement group_id="O4" value="-0.6" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="426"/>
                    <count group_id="O2" value="432"/>
                    <count group_id="O3" value="435"/>
                    <count group_id="O4" value="436"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="5.7"/>
                    <measurement group_id="O2" value="-2.3" spread="6.8"/>
                    <measurement group_id="O3" value="-2.6" spread="6.2"/>
                    <measurement group_id="O4" value="-0.5" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="424"/>
                    <count group_id="O2" value="424"/>
                    <count group_id="O3" value="428"/>
                    <count group_id="O4" value="440"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="6.0"/>
                    <measurement group_id="O2" value="-2.4" spread="7.2"/>
                    <measurement group_id="O3" value="-2.4" spread="6.1"/>
                    <measurement group_id="O4" value="-0.7" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Cholesterol (Ratio to Baseline)</title>
        <description>Change from baseline (week 0) in total cholesterol (mmol/L) at weeks 26, 52 and 78 is presented as ratio to baseline. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
        <time_frame>Week 0, week 26, week 52, week 78</time_frame>
        <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Cholesterol (Ratio to Baseline)</title>
          <description>Change from baseline (week 0) in total cholesterol (mmol/L) at weeks 26, 52 and 78 is presented as ratio to baseline. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
          <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
          <units>Ratio of total cholesterol</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="465"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="433"/>
                    <count group_id="O2" value="437"/>
                    <count group_id="O3" value="432"/>
                    <count group_id="O4" value="444"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="16.8"/>
                    <measurement group_id="O2" value="0.98" spread="17.5"/>
                    <measurement group_id="O3" value="0.97" spread="17.1"/>
                    <measurement group_id="O4" value="1.00" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="421"/>
                    <count group_id="O2" value="427"/>
                    <count group_id="O3" value="432"/>
                    <count group_id="O4" value="435"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="17.5"/>
                    <measurement group_id="O2" value="0.99" spread="18.5"/>
                    <measurement group_id="O3" value="0.98" spread="17.0"/>
                    <measurement group_id="O4" value="1.01" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="419"/>
                    <count group_id="O2" value="419"/>
                    <count group_id="O3" value="421"/>
                    <count group_id="O4" value="438"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="18.3"/>
                    <measurement group_id="O2" value="0.99" spread="19.3"/>
                    <measurement group_id="O3" value="0.99" spread="18.7"/>
                    <measurement group_id="O4" value="1.00" spread="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in LDL Cholesterol (Ratio to Baseline)</title>
        <description>Change from baseline (week 0) in low-density lipoprotein (LDL) cholesterol (mmol/L) at weeks 26, 52 and 78 is presented as ratio to baseline. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
        <time_frame>Week 0, week 26, week 52, week 78</time_frame>
        <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in LDL Cholesterol (Ratio to Baseline)</title>
          <description>Change from baseline (week 0) in low-density lipoprotein (LDL) cholesterol (mmol/L) at weeks 26, 52 and 78 is presented as ratio to baseline. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
          <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
          <units>Ratio of LDL cholesterol</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="465"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="433"/>
                    <count group_id="O2" value="437"/>
                    <count group_id="O3" value="431"/>
                    <count group_id="O4" value="444"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" spread="28.2"/>
                    <measurement group_id="O2" value="0.98" spread="28.0"/>
                    <measurement group_id="O3" value="0.98" spread="28.6"/>
                    <measurement group_id="O4" value="1.02" spread="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="421"/>
                    <count group_id="O2" value="427"/>
                    <count group_id="O3" value="431"/>
                    <count group_id="O4" value="435"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" spread="28.1"/>
                    <measurement group_id="O2" value="0.99" spread="29.7"/>
                    <measurement group_id="O3" value="0.99" spread="27.4"/>
                    <measurement group_id="O4" value="1.03" spread="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="419"/>
                    <count group_id="O2" value="419"/>
                    <count group_id="O3" value="420"/>
                    <count group_id="O4" value="438"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" spread="30.8"/>
                    <measurement group_id="O2" value="1.00" spread="30.2"/>
                    <measurement group_id="O3" value="1.00" spread="30.2"/>
                    <measurement group_id="O4" value="1.03" spread="32.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in VLDL Cholesterol (Ratio to Baseline)</title>
        <description>Change from baseline (week 0) in very-low-density lipoprotein (VLDL) cholesterol (mmol/L) at weeks 26, 52 and 78 is presented as ratio to baseline. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
        <time_frame>Week 0, week 26, week 52, week 78</time_frame>
        <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in VLDL Cholesterol (Ratio to Baseline)</title>
          <description>Change from baseline (week 0) in very-low-density lipoprotein (VLDL) cholesterol (mmol/L) at weeks 26, 52 and 78 is presented as ratio to baseline. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
          <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
          <units>Ratio of VLDL cholesterol</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="465"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="433"/>
                    <count group_id="O2" value="437"/>
                    <count group_id="O3" value="431"/>
                    <count group_id="O4" value="444"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" spread="36.4"/>
                    <measurement group_id="O2" value="0.96" spread="36.1"/>
                    <measurement group_id="O3" value="0.91" spread="36.3"/>
                    <measurement group_id="O4" value="0.97" spread="34.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="421"/>
                    <count group_id="O2" value="427"/>
                    <count group_id="O3" value="431"/>
                    <count group_id="O4" value="435"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="35.0"/>
                    <measurement group_id="O2" value="0.98" spread="39.1"/>
                    <measurement group_id="O3" value="0.93" spread="39.6"/>
                    <measurement group_id="O4" value="0.98" spread="34.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="419"/>
                    <count group_id="O2" value="419"/>
                    <count group_id="O3" value="420"/>
                    <count group_id="O4" value="438"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" spread="41.7"/>
                    <measurement group_id="O2" value="0.94" spread="41.5"/>
                    <measurement group_id="O3" value="0.91" spread="40.4"/>
                    <measurement group_id="O4" value="0.94" spread="39.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HDL Cholesterol (Ratio to Baseline)</title>
        <description>Change from baseline (week 0) in high-density lipoprotein (HDL) cholesterol (mmol/L) at weeks 26, 52 and 78 is presented as ratio to baseline. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
        <time_frame>Week 0, week 26, week 52, week 78</time_frame>
        <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HDL Cholesterol (Ratio to Baseline)</title>
          <description>Change from baseline (week 0) in high-density lipoprotein (HDL) cholesterol (mmol/L) at weeks 26, 52 and 78 is presented as ratio to baseline. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
          <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
          <units>Ratio of HDL cholesterol</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="465"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="433"/>
                    <count group_id="O2" value="437"/>
                    <count group_id="O3" value="431"/>
                    <count group_id="O4" value="444"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="13.6"/>
                    <measurement group_id="O2" value="0.99" spread="14.8"/>
                    <measurement group_id="O3" value="0.98" spread="14.9"/>
                    <measurement group_id="O4" value="0.99" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="421"/>
                    <count group_id="O2" value="427"/>
                    <count group_id="O3" value="431"/>
                    <count group_id="O4" value="435"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" spread="13.9"/>
                    <measurement group_id="O2" value="1.01" spread="14.3"/>
                    <measurement group_id="O3" value="1.01" spread="15.2"/>
                    <measurement group_id="O4" value="0.99" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="419"/>
                    <count group_id="O2" value="419"/>
                    <count group_id="O3" value="420"/>
                    <count group_id="O4" value="438"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="15.3"/>
                    <measurement group_id="O2" value="0.99" spread="15.6"/>
                    <measurement group_id="O3" value="1.00" spread="15.5"/>
                    <measurement group_id="O4" value="0.99" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Triglycerides (Ratio to Baseline)</title>
        <description>Change from baseline (week 0) in triglycerides (mmol/L) at weeks 26, 52 and 78 is presented as ratio to baseline. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
        <time_frame>Week 0, week 26, week 52, week 78</time_frame>
        <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Triglycerides (Ratio to Baseline)</title>
          <description>Change from baseline (week 0) in triglycerides (mmol/L) at weeks 26, 52 and 78 is presented as ratio to baseline. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
          <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
          <units>Ratio of triglycerides</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="465"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="433"/>
                    <count group_id="O2" value="437"/>
                    <count group_id="O3" value="431"/>
                    <count group_id="O4" value="444"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" spread="38.1"/>
                    <measurement group_id="O2" value="0.96" spread="39.2"/>
                    <measurement group_id="O3" value="0.92" spread="39.8"/>
                    <measurement group_id="O4" value="0.97" spread="36.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="421"/>
                    <count group_id="O2" value="427"/>
                    <count group_id="O3" value="431"/>
                    <count group_id="O4" value="435"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="35.7"/>
                    <measurement group_id="O2" value="0.97" spread="41.3"/>
                    <measurement group_id="O3" value="0.93" spread="42.3"/>
                    <measurement group_id="O4" value="0.98" spread="37.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="419"/>
                    <count group_id="O2" value="419"/>
                    <count group_id="O3" value="420"/>
                    <count group_id="O4" value="438"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" spread="43.9"/>
                    <measurement group_id="O2" value="0.94" spread="43.7"/>
                    <measurement group_id="O3" value="0.92" spread="43.1"/>
                    <measurement group_id="O4" value="0.93" spread="41.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Free Fatty Acids (Ratio to Baseline)</title>
        <description>Change from baseline (week 0) in free fatty acids (FFA) (mmol/L) at weeks 26, 52 and 78 is presented as ratio to baseline. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product. Because of an issue with the handling of the blood samples for FFA, all FFA data were considered invalid for this trial; thus, no conclusion with regards to FFA levels can be made based on the data presented here.</description>
        <time_frame>Week 0, week 26, week 52, week 78</time_frame>
        <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Free Fatty Acids (Ratio to Baseline)</title>
          <description>Change from baseline (week 0) in free fatty acids (FFA) (mmol/L) at weeks 26, 52 and 78 is presented as ratio to baseline. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product. Because of an issue with the handling of the blood samples for FFA, all FFA data were considered invalid for this trial; thus, no conclusion with regards to FFA levels can be made based on the data presented here.</description>
          <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
          <units>Ratio of FFA</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="465"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="426"/>
                    <count group_id="O2" value="428"/>
                    <count group_id="O3" value="426"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" spread="48.7"/>
                    <measurement group_id="O2" value="0.91" spread="50.4"/>
                    <measurement group_id="O3" value="0.88" spread="55.8"/>
                    <measurement group_id="O4" value="0.90" spread="49.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="419"/>
                    <count group_id="O2" value="420"/>
                    <count group_id="O3" value="426"/>
                    <count group_id="O4" value="432"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" spread="46.7"/>
                    <measurement group_id="O2" value="1.00" spread="47.9"/>
                    <measurement group_id="O3" value="0.96" spread="56.0"/>
                    <measurement group_id="O4" value="0.98" spread="47.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="415"/>
                    <count group_id="O2" value="413"/>
                    <count group_id="O3" value="414"/>
                    <count group_id="O4" value="435"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="54.2"/>
                    <measurement group_id="O2" value="0.87" spread="56.5"/>
                    <measurement group_id="O3" value="0.88" spread="56.3"/>
                    <measurement group_id="O4" value="0.87" spread="57.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in SMPG - Mean 7-point Profile</title>
        <description>Change from baseline (week 0) in mean 7-point self-measured plasma glucose (SMPG) profile. SMPG was recorded at the following 7 time points: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after dinner and at bedtime. Mean 7-point profile was defined as the area under the profile, calculated using the trapezoidal method, divided by the measurement time. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
        <time_frame>Week 0, week 26, week 52, week 78</time_frame>
        <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in SMPG - Mean 7-point Profile</title>
          <description>Change from baseline (week 0) in mean 7-point self-measured plasma glucose (SMPG) profile. SMPG was recorded at the following 7 time points: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after dinner and at bedtime. Mean 7-point profile was defined as the area under the profile, calculated using the trapezoidal method, divided by the measurement time. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
          <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="465"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="398"/>
                    <count group_id="O2" value="410"/>
                    <count group_id="O3" value="400"/>
                    <count group_id="O4" value="409"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="2.3"/>
                    <measurement group_id="O2" value="-1.5" spread="2.3"/>
                    <measurement group_id="O3" value="-1.7" spread="2.4"/>
                    <measurement group_id="O4" value="-1.2" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="399"/>
                    <count group_id="O2" value="405"/>
                    <count group_id="O3" value="401"/>
                    <count group_id="O4" value="414"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="2.4"/>
                    <measurement group_id="O2" value="-1.5" spread="2.5"/>
                    <measurement group_id="O3" value="-1.8" spread="2.4"/>
                    <measurement group_id="O4" value="-1.4" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="396"/>
                    <count group_id="O2" value="385"/>
                    <count group_id="O3" value="392"/>
                    <count group_id="O4" value="409"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="2.7"/>
                    <measurement group_id="O2" value="-1.5" spread="2.7"/>
                    <measurement group_id="O3" value="-1.7" spread="2.2"/>
                    <measurement group_id="O4" value="-1.3" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in SMPG - Mean Postprandial Increment Over All Meals</title>
        <description>Change from baseline (week 0) in the average of the post-prandial increments over all meals was evaluated at weeks 26, 52 and 78. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
        <time_frame>Week 0, week 26, week 52, week 78</time_frame>
        <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in SMPG - Mean Postprandial Increment Over All Meals</title>
          <description>Change from baseline (week 0) in the average of the post-prandial increments over all meals was evaluated at weeks 26, 52 and 78. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
          <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="465"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="400"/>
                    <count group_id="O2" value="411"/>
                    <count group_id="O3" value="402"/>
                    <count group_id="O4" value="408"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="2.1"/>
                    <measurement group_id="O2" value="-0.4" spread="2.1"/>
                    <measurement group_id="O3" value="-0.6" spread="2.1"/>
                    <measurement group_id="O4" value="-0.6" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="400"/>
                    <count group_id="O2" value="406"/>
                    <count group_id="O3" value="402"/>
                    <count group_id="O4" value="413"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="2.0"/>
                    <measurement group_id="O2" value="-0.4" spread="2.1"/>
                    <measurement group_id="O3" value="-0.7" spread="2.0"/>
                    <measurement group_id="O4" value="-0.4" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="398"/>
                    <count group_id="O2" value="387"/>
                    <count group_id="O3" value="392"/>
                    <count group_id="O4" value="409"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="2.1"/>
                    <measurement group_id="O2" value="-0.4" spread="2.1"/>
                    <measurement group_id="O3" value="-0.6" spread="2.0"/>
                    <measurement group_id="O4" value="-0.6" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Who Achieve HbA1c &lt;7.0% (53 mmol/Mol) ADA Target (Yes/no)</title>
        <description>Participants who achieved HbA1c &lt;7.0% (American Diabetes Association (ADA) target) (yes/no), was evaluated at weeks 26, 52 and 78. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
        <time_frame>Week 26, week 52, week 78</time_frame>
        <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Who Achieve HbA1c &lt;7.0% (53 mmol/Mol) ADA Target (Yes/no)</title>
          <description>Participants who achieved HbA1c &lt;7.0% (American Diabetes Association (ADA) target) (yes/no), was evaluated at weeks 26, 52 and 78. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
          <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="465"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="435"/>
                    <count group_id="O2" value="438"/>
                    <count group_id="O3" value="436"/>
                    <count group_id="O4" value="446"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="192"/>
                    <measurement group_id="O3" value="246"/>
                    <measurement group_id="O4" value="144"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="319"/>
                    <measurement group_id="O2" value="246"/>
                    <measurement group_id="O3" value="190"/>
                    <measurement group_id="O4" value="302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="427"/>
                    <count group_id="O2" value="431"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="436"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="168"/>
                    <measurement group_id="O3" value="238"/>
                    <measurement group_id="O4" value="138"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="314"/>
                    <measurement group_id="O2" value="263"/>
                    <measurement group_id="O3" value="196"/>
                    <measurement group_id="O4" value="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="421"/>
                    <count group_id="O2" value="424"/>
                    <count group_id="O3" value="425"/>
                    <count group_id="O4" value="439"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="165"/>
                    <measurement group_id="O3" value="191"/>
                    <measurement group_id="O4" value="129"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="308"/>
                    <measurement group_id="O2" value="259"/>
                    <measurement group_id="O3" value="234"/>
                    <measurement group_id="O4" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Who Achieve HbA1c ≤6.5% (48 mmol/Mol) AACE Target (Yes/no)</title>
        <description>Participants who achieved HbA1c less than or equal to 6.5% (American Association of Clinical Endocrinologists (AACE) target) (yes/no) at weeks 26, 52 and 78 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
        <time_frame>Week 26, week 52, week 78</time_frame>
        <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Who Achieve HbA1c ≤6.5% (48 mmol/Mol) AACE Target (Yes/no)</title>
          <description>Participants who achieved HbA1c less than or equal to 6.5% (American Association of Clinical Endocrinologists (AACE) target) (yes/no) at weeks 26, 52 and 78 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
          <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="465"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="435"/>
                    <count group_id="O2" value="438"/>
                    <count group_id="O3" value="436"/>
                    <count group_id="O4" value="446"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="116"/>
                    <measurement group_id="O3" value="161"/>
                    <measurement group_id="O4" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="380"/>
                    <measurement group_id="O2" value="322"/>
                    <measurement group_id="O3" value="275"/>
                    <measurement group_id="O4" value="385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="427"/>
                    <count group_id="O2" value="431"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="436"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="146"/>
                    <measurement group_id="O4" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="372"/>
                    <measurement group_id="O2" value="332"/>
                    <measurement group_id="O3" value="288"/>
                    <measurement group_id="O4" value="377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="421"/>
                    <count group_id="O2" value="424"/>
                    <count group_id="O3" value="425"/>
                    <count group_id="O4" value="439"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="129"/>
                    <measurement group_id="O4" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="372"/>
                    <measurement group_id="O2" value="324"/>
                    <measurement group_id="O3" value="296"/>
                    <measurement group_id="O4" value="379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Who Achieve Weight Loss ≥5% (Yes/no)</title>
        <description>Participants who achieved weight loss more than or equal to 5% of their baseline body weight (yes/no) at weeks 26, 52 and 78 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
        <time_frame>Week 26, week 52, week 78</time_frame>
        <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Who Achieve Weight Loss ≥5% (Yes/no)</title>
          <description>Participants who achieved weight loss more than or equal to 5% of their baseline body weight (yes/no) at weeks 26, 52 and 78 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
          <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="465"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="440"/>
                    <count group_id="O3" value="439"/>
                    <count group_id="O4" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="81"/>
                    <measurement group_id="O3" value="131"/>
                    <measurement group_id="O4" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="385"/>
                    <measurement group_id="O2" value="359"/>
                    <measurement group_id="O3" value="308"/>
                    <measurement group_id="O4" value="402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="433"/>
                    <count group_id="O3" value="435"/>
                    <count group_id="O4" value="437"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="118"/>
                    <measurement group_id="O3" value="147"/>
                    <measurement group_id="O4" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="362"/>
                    <measurement group_id="O2" value="315"/>
                    <measurement group_id="O3" value="288"/>
                    <measurement group_id="O4" value="387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="425"/>
                    <count group_id="O3" value="428"/>
                    <count group_id="O4" value="443"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="115"/>
                    <measurement group_id="O3" value="139"/>
                    <measurement group_id="O4" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="342"/>
                    <measurement group_id="O2" value="310"/>
                    <measurement group_id="O3" value="289"/>
                    <measurement group_id="O4" value="384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Who Achieve Weight Loss ≥10% (Yes/no)</title>
        <description>Participants who achieved weight loss more than or equal to 10% of their baseline body weight (yes/no) at weeks 26, 52 and 78 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
        <time_frame>Week 26, week 52, week 78</time_frame>
        <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Who Achieve Weight Loss ≥10% (Yes/no)</title>
          <description>Participants who achieved weight loss more than or equal to 10% of their baseline body weight (yes/no) at weeks 26, 52 and 78 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
          <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="465"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="440"/>
                    <count group_id="O3" value="439"/>
                    <count group_id="O4" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="433"/>
                    <measurement group_id="O2" value="417"/>
                    <measurement group_id="O3" value="410"/>
                    <measurement group_id="O4" value="439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="433"/>
                    <count group_id="O3" value="435"/>
                    <count group_id="O4" value="437"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="415"/>
                    <measurement group_id="O2" value="402"/>
                    <measurement group_id="O3" value="387"/>
                    <measurement group_id="O4" value="426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="425"/>
                    <count group_id="O3" value="428"/>
                    <count group_id="O4" value="443"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="413"/>
                    <measurement group_id="O2" value="382"/>
                    <measurement group_id="O3" value="382"/>
                    <measurement group_id="O4" value="426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Who Achieve HbA1c &lt;7.0 % (53 mmol/Mol) Without Hypoglycaemia (Severe or BG Confirmed Symptomatic Hypoglycaemia) and no Weight Gain (Yes/no)</title>
        <description>Participants who achieved HbA1c less than 7.0 % without severe or blood glucose (BG) confirmed symptomatic hypoglycaemia and without weight gain (yes/no) at weeks 26, 52 and 78 are presented. Severe hypoglycaemia was defined as an episode requiring assistance of another person to actively administer carbohydrate or glucagon, or take other corrective actions. BG-confirmed symptomatic hypoglycaemia was defined as an episode with plasma glucose value &lt;3.1 mmol/L with symptoms consistent with hypoglycaemia. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
        <time_frame>Week 26, week 52, week 78</time_frame>
        <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Who Achieve HbA1c &lt;7.0 % (53 mmol/Mol) Without Hypoglycaemia (Severe or BG Confirmed Symptomatic Hypoglycaemia) and no Weight Gain (Yes/no)</title>
          <description>Participants who achieved HbA1c less than 7.0 % without severe or blood glucose (BG) confirmed symptomatic hypoglycaemia and without weight gain (yes/no) at weeks 26, 52 and 78 are presented. Severe hypoglycaemia was defined as an episode requiring assistance of another person to actively administer carbohydrate or glucagon, or take other corrective actions. BG-confirmed symptomatic hypoglycaemia was defined as an episode with plasma glucose value &lt;3.1 mmol/L with symptoms consistent with hypoglycaemia. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
          <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="465"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="435"/>
                    <count group_id="O2" value="438"/>
                    <count group_id="O3" value="436"/>
                    <count group_id="O4" value="446"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="155"/>
                    <measurement group_id="O3" value="208"/>
                    <measurement group_id="O4" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="348"/>
                    <measurement group_id="O2" value="283"/>
                    <measurement group_id="O3" value="228"/>
                    <measurement group_id="O4" value="356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="427"/>
                    <count group_id="O2" value="431"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="436"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="134"/>
                    <measurement group_id="O3" value="195"/>
                    <measurement group_id="O4" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="340"/>
                    <measurement group_id="O2" value="297"/>
                    <measurement group_id="O3" value="239"/>
                    <measurement group_id="O4" value="349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="421"/>
                    <count group_id="O2" value="424"/>
                    <count group_id="O3" value="425"/>
                    <count group_id="O4" value="439"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="136"/>
                    <measurement group_id="O3" value="151"/>
                    <measurement group_id="O4" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="336"/>
                    <measurement group_id="O2" value="288"/>
                    <measurement group_id="O3" value="274"/>
                    <measurement group_id="O4" value="355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Who Achieve HbA1c Reduction ≥1% (10.9 mmol/Mol) and Weight Loss ≥3% (Yes/no)</title>
        <description>Participants who achieved HbA1c reduction more than or equal to 1% of their baseline HbA1c and weight loss of more than or equal to 3% of their baseline body weight (yes/no) at weeks 26, 52 and 78 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
        <time_frame>Week 26, week 52, week 78</time_frame>
        <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Who Achieve HbA1c Reduction ≥1% (10.9 mmol/Mol) and Weight Loss ≥3% (Yes/no)</title>
          <description>Participants who achieved HbA1c reduction more than or equal to 1% of their baseline HbA1c and weight loss of more than or equal to 3% of their baseline body weight (yes/no) at weeks 26, 52 and 78 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
          <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="465"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="435"/>
                    <count group_id="O2" value="438"/>
                    <count group_id="O3" value="436"/>
                    <count group_id="O4" value="446"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="117"/>
                    <measurement group_id="O3" value="166"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="380"/>
                    <measurement group_id="O2" value="321"/>
                    <measurement group_id="O3" value="270"/>
                    <measurement group_id="O4" value="403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="427"/>
                    <count group_id="O2" value="431"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="436"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="106"/>
                    <measurement group_id="O3" value="164"/>
                    <measurement group_id="O4" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="354"/>
                    <measurement group_id="O2" value="325"/>
                    <measurement group_id="O3" value="270"/>
                    <measurement group_id="O4" value="385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="421"/>
                    <count group_id="O2" value="424"/>
                    <count group_id="O3" value="425"/>
                    <count group_id="O4" value="439"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="113"/>
                    <measurement group_id="O3" value="149"/>
                    <measurement group_id="O4" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="345"/>
                    <measurement group_id="O2" value="311"/>
                    <measurement group_id="O3" value="276"/>
                    <measurement group_id="O4" value="379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Additional Anti-diabetic Medication</title>
        <description>Presented results are the number of participants who had taken additional anti-diabetic medication anytime during the periods, from week 0 to week 26, week 0 to week 52 and week 0 to week 78. Additional anti-diabetic medication was defined as any new anti-diabetic medication used for more than 21 days with the initiation at or after randomisation (week 0) and before (planned) end-of-treatment (week 78), and/or intensification of anti-diabetic medication (a more than 20% increase in dose relative to baseline) for more than 21 days with the intensification at or after randomisation and before (planned) end-of-treatment. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
        <time_frame>Weeks 0-78</time_frame>
        <population>Overall number of participants analyzed = FAS which comprised all randomised participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Additional Anti-diabetic Medication</title>
          <description>Presented results are the number of participants who had taken additional anti-diabetic medication anytime during the periods, from week 0 to week 26, week 0 to week 52 and week 0 to week 78. Additional anti-diabetic medication was defined as any new anti-diabetic medication used for more than 21 days with the initiation at or after randomisation (week 0) and before (planned) end-of-treatment (week 78), and/or intensification of anti-diabetic medication (a more than 20% increase in dose relative to baseline) for more than 21 days with the intensification at or after randomisation and before (planned) end-of-treatment. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
          <population>Overall number of participants analyzed = FAS which comprised all randomised participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="465"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 to week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0 to week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0 to week 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179"/>
                    <measurement group_id="O2" value="119"/>
                    <measurement group_id="O3" value="75"/>
                    <measurement group_id="O4" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Time to initiation of additional anti-diabetic medication was analysed using a Cox proportional hazards model with treatment, strata, and region as categorical fixed effects and baseline HbA1c as covariate. Withdrawal for any reason or lost to follow-up contributed to the analysis as events (initiation of additional anti-diabetic medication). Censoring time was one day before planned end of treatment.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This hypothesis was not controlled for multiplicity.</non_inferiority_desc>
            <p_value>=0.0063</p_value>
            <p_value_desc>Unadjusted two-sided p-value for test of no difference from 1.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.09</ci_lower_limit>
            <ci_upper_limit>1.65</ci_upper_limit>
            <estimate_desc>Oral semaglutide 3 mg / Sitagliptin 100 mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Time to initiation of additional anti-diabetic medication was analysed using a Cox proportional hazards model with treatment, strata, and region as categorical fixed effects and baseline HbA1c as covariate. Withdrawal for any reason or lost to follow-up contributed to the analysis as events (initiation of additional anti-diabetic medication). Censoring time was one day before planned end of treatment.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This hypothesis was not controlled for multiplicity.</non_inferiority_desc>
            <p_value>=0.0221</p_value>
            <p_value_desc>Unadjusted two-sided p-value for test of no difference from 1.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
            <estimate_desc>Oral semaglutide 7 mg / Sitagliptin 100 mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Time to initiation of additional anti-diabetic medication was analysed using a Cox proportional hazards model with treatment, strata, and region as categorical fixed effects and baseline HbA1c as covariate. Withdrawal for any reason or lost to follow-up contributed to the analysis as events (initiation of additional anti-diabetic medication). Censoring time was one day before planned end of treatment.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This hypothesis was not controlled for multiplicity.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Unadjusted two-sided p-value for test of no difference from 1.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.41</ci_lower_limit>
            <ci_upper_limit>0.68</ci_upper_limit>
            <estimate_desc>Oral semaglutide 14 mg / Sitagliptin 100 mg</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Rescue Medication</title>
        <description>Presented results are the number of participants who had taken rescue medication anytime during the periods, from week 0 to week 26, week 0 to week 52 and week 0 to week 78. Rescue medication was defined as any new anti-diabetic medication used as add-on to trial product and used for more than 21 days with the initiation at or after randomisation (week 0) and before last day on trial product, and/or intensification of anti-diabetic medication (a more than 20% increase in dose relative to baseline) for more than 21 days with the intensification at or after randomisation and before last day on trial product. Results are based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was on treatment with trial product, excluding any period after initiation of rescue medication and/or premature trial product discontinuation.</description>
        <time_frame>Weeks 0-78</time_frame>
        <population>Overall number of participants analyzed = FAS which comprised all randomised participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Rescue Medication</title>
          <description>Presented results are the number of participants who had taken rescue medication anytime during the periods, from week 0 to week 26, week 0 to week 52 and week 0 to week 78. Rescue medication was defined as any new anti-diabetic medication used as add-on to trial product and used for more than 21 days with the initiation at or after randomisation (week 0) and before last day on trial product, and/or intensification of anti-diabetic medication (a more than 20% increase in dose relative to baseline) for more than 21 days with the intensification at or after randomisation and before last day on trial product. Results are based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was on treatment with trial product, excluding any period after initiation of rescue medication and/or premature trial product discontinuation.</description>
          <population>Overall number of participants analyzed = FAS which comprised all randomised participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="465"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 to week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0 to week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0 to week 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="103"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Time to initiation of rescue medication was analysed using a Cox proportional hazards model with treatment, strata, and region as categorical fixed effects and baseline HbA1c as covariate. Censoring time was one day before last day on trial product.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This hypothesis was not controlled for multiplicity.</non_inferiority_desc>
            <p_value>=0.0160</p_value>
            <p_value_desc>Unadjusted two-sided p-value for test of no difference from 1.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
            <estimate_desc>Oral semaglutide 3 mg / Sitagliptin 100 mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Time to initiation of rescue medication was analysed using a Cox proportional hazards model with treatment, strata, and region as categorical fixed effects and baseline HbA1c as covariate. Censoring time was one day before last day on trial product.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This hypothesis was not controlled for multiplicity.</non_inferiority_desc>
            <p_value>=0.0022</p_value>
            <p_value_desc>Unadjusted two-sided p-value for test of no difference from 1.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
            <estimate_desc>Oral semaglutide 7 mg / Sitagliptin 100 mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Time to initiation of rescue medication was analysed using a Cox proportional hazards model with treatment, strata, and region as categorical fixed effects and baseline HbA1c as covariate. Censoring time was one day before last day on trial product.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This hypothesis was not controlled for multiplicity.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Unadjusted two-sided p-value for test of no difference from 1.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.22</ci_lower_limit>
            <ci_upper_limit>0.43</ci_upper_limit>
            <estimate_desc>Oral semaglutide 14 mg / Sitagliptin 100 mg</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of TEAEs During Exposure to Trial Product</title>
        <description>Treatment emergent adverse events (TEAEs) were recorded from week 0 to week 83 (78-week treatment period plus the 5-week follow-up period). Adverse events (AEs) with onset during the on-treatment observation period were considered treatment-emergent. On-treatment observation period: Time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.</description>
        <time_frame>Weeks 0-83</time_frame>
        <population>Overall number of participants analyzed = safety analysis set (SAS) which comprised all randomised participants who received at least one dose of trial product.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of TEAEs During Exposure to Trial Product</title>
          <description>Treatment emergent adverse events (TEAEs) were recorded from week 0 to week 83 (78-week treatment period plus the 5-week follow-up period). Adverse events (AEs) with onset during the on-treatment observation period were considered treatment-emergent. On-treatment observation period: Time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.</description>
          <population>Overall number of participants analyzed = safety analysis set (SAS) which comprised all randomised participants who received at least one dose of trial product.</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="464"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1774"/>
                    <measurement group_id="O2" value="1686"/>
                    <measurement group_id="O3" value="1824"/>
                    <measurement group_id="O4" value="1852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Amylase (Ratio to Baseline)</title>
        <description>Change from baseline (week 0) in amylase (units/litre (U/L)) at weeks 26, 52 and 78 is presented as ratio to baseline. Results are based on the data from the on-treatment observation period which was the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.</description>
        <time_frame>Week 0, week 26, week 52, week 78</time_frame>
        <population>Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Amylase (Ratio to Baseline)</title>
          <description>Change from baseline (week 0) in amylase (units/litre (U/L)) at weeks 26, 52 and 78 is presented as ratio to baseline. Results are based on the data from the on-treatment observation period which was the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.</description>
          <population>Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product. Number Analyzed = number of participants with available data.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="464"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="415"/>
                    <count group_id="O2" value="421"/>
                    <count group_id="O3" value="401"/>
                    <count group_id="O4" value="433"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" spread="25.6"/>
                    <measurement group_id="O2" value="1.07" spread="27.5"/>
                    <measurement group_id="O3" value="1.14" spread="30.4"/>
                    <measurement group_id="O4" value="1.08" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="391"/>
                    <count group_id="O2" value="403"/>
                    <count group_id="O3" value="388"/>
                    <count group_id="O4" value="414"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" spread="25.8"/>
                    <measurement group_id="O2" value="1.09" spread="28.8"/>
                    <measurement group_id="O3" value="1.11" spread="29.0"/>
                    <measurement group_id="O4" value="1.08" spread="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="377"/>
                    <count group_id="O2" value="392"/>
                    <count group_id="O3" value="366"/>
                    <count group_id="O4" value="402"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" spread="28.4"/>
                    <measurement group_id="O2" value="1.09" spread="29.2"/>
                    <measurement group_id="O3" value="1.09" spread="25.5"/>
                    <measurement group_id="O4" value="1.08" spread="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Lipase (Ratio to Baseline)</title>
        <description>Change from baseline (week 0) in lipase (U/L) at weeks 26, 52 and 78 is presented as ratio to baseline. Results are based on the data from the on-treatment observation period which was the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.</description>
        <time_frame>Week 0, week 26, week 52, week 78</time_frame>
        <population>Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lipase (Ratio to Baseline)</title>
          <description>Change from baseline (week 0) in lipase (U/L) at weeks 26, 52 and 78 is presented as ratio to baseline. Results are based on the data from the on-treatment observation period which was the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.</description>
          <population>Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product. Number Analyzed = number of participants with available data.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="464"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="415"/>
                    <count group_id="O2" value="420"/>
                    <count group_id="O3" value="401"/>
                    <count group_id="O4" value="433"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" spread="52.6"/>
                    <measurement group_id="O2" value="1.13" spread="60.1"/>
                    <measurement group_id="O3" value="1.26" spread="64.9"/>
                    <measurement group_id="O4" value="1.14" spread="50.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="391"/>
                    <count group_id="O2" value="403"/>
                    <count group_id="O3" value="388"/>
                    <count group_id="O4" value="414"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="51.5"/>
                    <measurement group_id="O2" value="1.15" spread="59.4"/>
                    <measurement group_id="O3" value="1.25" spread="56.6"/>
                    <measurement group_id="O4" value="1.15" spread="54.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="377"/>
                    <count group_id="O2" value="392"/>
                    <count group_id="O3" value="366"/>
                    <count group_id="O4" value="402"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" spread="56.2"/>
                    <measurement group_id="O2" value="1.14" spread="61.9"/>
                    <measurement group_id="O3" value="1.18" spread="54.3"/>
                    <measurement group_id="O4" value="1.10" spread="50.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pulse Rate</title>
        <description>Change from baseline (week 0) in pulse rate was evaluated at weeks 26, 52 and 78. Results are based on the data from the on-treatment observation period which was the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.</description>
        <time_frame>Week 0, week 26, week 52, week 78</time_frame>
        <population>Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pulse Rate</title>
          <description>Change from baseline (week 0) in pulse rate was evaluated at weeks 26, 52 and 78. Results are based on the data from the on-treatment observation period which was the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.</description>
          <population>Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product. Number Analyzed = number of participants with available data.</population>
          <units>Beats/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="464"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="419"/>
                    <count group_id="O2" value="422"/>
                    <count group_id="O3" value="406"/>
                    <count group_id="O4" value="435"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="9"/>
                    <measurement group_id="O2" value="2" spread="9"/>
                    <measurement group_id="O3" value="3" spread="10"/>
                    <measurement group_id="O4" value="0" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="396"/>
                    <count group_id="O2" value="406"/>
                    <count group_id="O3" value="391"/>
                    <count group_id="O4" value="416"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="10"/>
                    <measurement group_id="O2" value="2" spread="9"/>
                    <measurement group_id="O3" value="2" spread="10"/>
                    <measurement group_id="O4" value="-0" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="382"/>
                    <count group_id="O2" value="394"/>
                    <count group_id="O3" value="368"/>
                    <count group_id="O4" value="405"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="10"/>
                    <measurement group_id="O2" value="1" spread="10"/>
                    <measurement group_id="O3" value="2" spread="10"/>
                    <measurement group_id="O4" value="0" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in SBP and DBP</title>
        <description>Change from baseline (week 0) in systolic blood pressure (SBP) and diastolic blood pressure (DBP) was evaluated at weeks 26, 52 and 78. Results are based on the data from the on-treatment observation period which was the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.</description>
        <time_frame>Week 0, week 26, week 52, week 78</time_frame>
        <population>Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in SBP and DBP</title>
          <description>Change from baseline (week 0) in systolic blood pressure (SBP) and diastolic blood pressure (DBP) was evaluated at weeks 26, 52 and 78. Results are based on the data from the on-treatment observation period which was the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.</description>
          <population>Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product. Number Analyzed = number of participants with available data.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="464"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP: Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="419"/>
                    <count group_id="O2" value="422"/>
                    <count group_id="O3" value="406"/>
                    <count group_id="O4" value="435"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" spread="14"/>
                    <measurement group_id="O2" value="-2" spread="15"/>
                    <measurement group_id="O3" value="-3" spread="14"/>
                    <measurement group_id="O4" value="-2" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP: Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="397"/>
                    <count group_id="O2" value="406"/>
                    <count group_id="O3" value="391"/>
                    <count group_id="O4" value="416"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" spread="15"/>
                    <measurement group_id="O2" value="-4" spread="14"/>
                    <measurement group_id="O3" value="-3" spread="15"/>
                    <measurement group_id="O4" value="-1" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP: Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="382"/>
                    <count group_id="O2" value="394"/>
                    <count group_id="O3" value="369"/>
                    <count group_id="O4" value="405"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" spread="15"/>
                    <measurement group_id="O2" value="-3" spread="15"/>
                    <measurement group_id="O3" value="-3" spread="14"/>
                    <measurement group_id="O4" value="0" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="419"/>
                    <count group_id="O2" value="422"/>
                    <count group_id="O3" value="406"/>
                    <count group_id="O4" value="435"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="9"/>
                    <measurement group_id="O2" value="-0" spread="9"/>
                    <measurement group_id="O3" value="-1" spread="9"/>
                    <measurement group_id="O4" value="-0" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="397"/>
                    <count group_id="O2" value="406"/>
                    <count group_id="O3" value="391"/>
                    <count group_id="O4" value="416"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" spread="9"/>
                    <measurement group_id="O2" value="-1" spread="9"/>
                    <measurement group_id="O3" value="-1" spread="9"/>
                    <measurement group_id="O4" value="-1" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP: Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="382"/>
                    <count group_id="O2" value="394"/>
                    <count group_id="O3" value="369"/>
                    <count group_id="O4" value="405"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="10"/>
                    <measurement group_id="O2" value="-1" spread="10"/>
                    <measurement group_id="O3" value="-1" spread="10"/>
                    <measurement group_id="O4" value="-1" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in ECG Evaluation</title>
        <description>Change from baseline (week 0) in electrocardiogram (ECG) was evaluated at weeks 26, 52 and 78. Change from baseline results are presented as shift in findings (normal, abnormal and not clinically significant (NCS) and abnormal and clinically significant (CS)) from week 0 to week 26, 52 and 78. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
        <time_frame>Week 0, week 26, week 52, week 78</time_frame>
        <population>Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ECG Evaluation</title>
          <description>Change from baseline (week 0) in electrocardiogram (ECG) was evaluated at weeks 26, 52 and 78. Change from baseline results are presented as shift in findings (normal, abnormal and not clinically significant (NCS) and abnormal and clinically significant (CS)) from week 0 to week 26, 52 and 78. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
          <population>Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product. Number Analyzed = number of participants with available data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="464"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal (week 0) to normal (week 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="253"/>
                    <count group_id="O2" value="261"/>
                    <count group_id="O3" value="254"/>
                    <count group_id="O4" value="249"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211"/>
                    <measurement group_id="O2" value="214"/>
                    <measurement group_id="O3" value="230"/>
                    <measurement group_id="O4" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal (week 0) to abnormal NCS (week 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="253"/>
                    <count group_id="O2" value="261"/>
                    <count group_id="O3" value="254"/>
                    <count group_id="O4" value="249"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal (week 0) to abnormal CS (week 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="253"/>
                    <count group_id="O2" value="261"/>
                    <count group_id="O3" value="254"/>
                    <count group_id="O4" value="249"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal (week 0) NCS to normal (week 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="173"/>
                    <count group_id="O3" value="176"/>
                    <count group_id="O4" value="186"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal (week 0) NCS to abnormal NCS (week 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="173"/>
                    <count group_id="O3" value="176"/>
                    <count group_id="O4" value="186"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                    <measurement group_id="O2" value="128"/>
                    <measurement group_id="O3" value="133"/>
                    <measurement group_id="O4" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal (week 0) NCS to abnormal CS (week 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="173"/>
                    <count group_id="O3" value="176"/>
                    <count group_id="O4" value="186"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal (week 0) CS to normal (week 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal (week 0) CS to abnormal NCS (week 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal (week 0) CS to abnormal CS (week 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal (week 0) to normal (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="255"/>
                    <count group_id="O3" value="253"/>
                    <count group_id="O4" value="248"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196"/>
                    <measurement group_id="O2" value="218"/>
                    <measurement group_id="O3" value="219"/>
                    <measurement group_id="O4" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal (week 0) to abnormal NCS (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="255"/>
                    <count group_id="O3" value="253"/>
                    <count group_id="O4" value="248"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal (week 0) to abnormal CS (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="255"/>
                    <count group_id="O3" value="253"/>
                    <count group_id="O4" value="248"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal (week 0) NCS to normal (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="173"/>
                    <count group_id="O3" value="174"/>
                    <count group_id="O4" value="178"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="56"/>
                    <measurement group_id="O4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal (week 0) NCS to abnormal NCS (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="173"/>
                    <count group_id="O3" value="174"/>
                    <count group_id="O4" value="178"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="123"/>
                    <measurement group_id="O3" value="118"/>
                    <measurement group_id="O4" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal (week 0) NCS to abnormal CS (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="173"/>
                    <count group_id="O3" value="174"/>
                    <count group_id="O4" value="178"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal (week 0) CS to normal (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal (week 0) CS to abnormal NCS (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal (week 0) CS to abnormal CS (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal (week 0) to normal (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="240"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="251"/>
                    <count group_id="O4" value="249"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196"/>
                    <measurement group_id="O2" value="201"/>
                    <measurement group_id="O3" value="219"/>
                    <measurement group_id="O4" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal (week 0) to abnormal NCS (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="240"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="251"/>
                    <count group_id="O4" value="249"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal (week 0) to abnormal CS (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="240"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="251"/>
                    <count group_id="O4" value="249"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal (week 0) NCS to normal (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="168"/>
                    <count group_id="O4" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal (week 0) NCS to abnormal NCS (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="168"/>
                    <count group_id="O4" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="125"/>
                    <measurement group_id="O3" value="114"/>
                    <measurement group_id="O4" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal (week 0) NCS to abnormal CS (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="168"/>
                    <count group_id="O4" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal (week 0) CS to normal (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal (week 0) CS to abnormal NCS (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal (week 0) CS to abnormal CS (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physical Examination</title>
        <description>Participants with physical examination findings, normal, abnormal NCS and abnormal CS at baseline (weeks -2), weeks 52 and 78 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product. Results are presented for the following examinations: 1) Cardiovascular system; 2) Central and peripheral nervous system; 3) Gastrointestinal system, incl. mouth; 4) General appearance; 5) Head, ears, eyes, nose, throat, neck; 6) Lymph node palpation; 7) Musculoskeletal system; 8) Respiratory system; 9) Skin; 10) Thyroid gland.</description>
        <time_frame>Week -2, week 52, week 78</time_frame>
        <population>Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Physical Examination</title>
          <description>Participants with physical examination findings, normal, abnormal NCS and abnormal CS at baseline (weeks -2), weeks 52 and 78 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product. Results are presented for the following examinations: 1) Cardiovascular system; 2) Central and peripheral nervous system; 3) Gastrointestinal system, incl. mouth; 4) General appearance; 5) Head, ears, eyes, nose, throat, neck; 6) Lymph node palpation; 7) Musculoskeletal system; 8) Respiratory system; 9) Skin; 10) Thyroid gland.</description>
          <population>Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product. Number Analyzed = number of participants with available data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="464"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1) Cardiovascular system (week -2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="466"/>
                    <count group_id="O2" value="464"/>
                    <count group_id="O3" value="465"/>
                    <count group_id="O4" value="466"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="431"/>
                    <measurement group_id="O2" value="425"/>
                    <measurement group_id="O3" value="432"/>
                    <measurement group_id="O4" value="424"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1) Cardiovascular system (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="427"/>
                    <count group_id="O2" value="433"/>
                    <count group_id="O3" value="435"/>
                    <count group_id="O4" value="436"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="398"/>
                    <measurement group_id="O2" value="396"/>
                    <measurement group_id="O3" value="404"/>
                    <measurement group_id="O4" value="399"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1) Cardiovascular system (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="424"/>
                    <count group_id="O2" value="423"/>
                    <count group_id="O3" value="428"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="395"/>
                    <measurement group_id="O2" value="386"/>
                    <measurement group_id="O3" value="402"/>
                    <measurement group_id="O4" value="399"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2) Central and peripheral nervous system (week -2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="466"/>
                    <count group_id="O2" value="463"/>
                    <count group_id="O3" value="464"/>
                    <count group_id="O4" value="466"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="410"/>
                    <measurement group_id="O2" value="415"/>
                    <measurement group_id="O3" value="407"/>
                    <measurement group_id="O4" value="409"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2) Central and peripheral nervous system (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="427"/>
                    <count group_id="O2" value="433"/>
                    <count group_id="O3" value="435"/>
                    <count group_id="O4" value="435"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="376"/>
                    <measurement group_id="O2" value="382"/>
                    <measurement group_id="O3" value="388"/>
                    <measurement group_id="O4" value="385"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2) Central and peripheral nervous system (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="424"/>
                    <count group_id="O2" value="423"/>
                    <count group_id="O3" value="428"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="377"/>
                    <measurement group_id="O2" value="376"/>
                    <measurement group_id="O3" value="384"/>
                    <measurement group_id="O4" value="399"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3) Gastrointestinal system, incl. mouth (week -2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="466"/>
                    <count group_id="O2" value="464"/>
                    <count group_id="O3" value="465"/>
                    <count group_id="O4" value="466"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="419"/>
                    <measurement group_id="O2" value="421"/>
                    <measurement group_id="O3" value="420"/>
                    <measurement group_id="O4" value="421"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3) Gastrointestinal system, incl. mouth (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="426"/>
                    <count group_id="O2" value="433"/>
                    <count group_id="O3" value="435"/>
                    <count group_id="O4" value="436"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="386"/>
                    <measurement group_id="O2" value="402"/>
                    <measurement group_id="O3" value="397"/>
                    <measurement group_id="O4" value="394"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3) Gastrointestinal system, incl. mouth (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="424"/>
                    <count group_id="O2" value="423"/>
                    <count group_id="O3" value="428"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="398"/>
                    <measurement group_id="O2" value="387"/>
                    <measurement group_id="O3" value="393"/>
                    <measurement group_id="O4" value="408"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4) General appearance (week -2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="466"/>
                    <count group_id="O2" value="464"/>
                    <count group_id="O3" value="465"/>
                    <count group_id="O4" value="466"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="407"/>
                    <measurement group_id="O2" value="405"/>
                    <measurement group_id="O3" value="412"/>
                    <measurement group_id="O4" value="405"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4) General appearance (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="426"/>
                    <count group_id="O2" value="433"/>
                    <count group_id="O3" value="435"/>
                    <count group_id="O4" value="436"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="381"/>
                    <measurement group_id="O2" value="384"/>
                    <measurement group_id="O3" value="390"/>
                    <measurement group_id="O4" value="385"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4) General appearance (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="424"/>
                    <count group_id="O2" value="423"/>
                    <count group_id="O3" value="428"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="379"/>
                    <measurement group_id="O2" value="373"/>
                    <measurement group_id="O3" value="388"/>
                    <measurement group_id="O4" value="394"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5) Head, ears, eyes, nose, throat, neck (week -2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="466"/>
                    <count group_id="O2" value="464"/>
                    <count group_id="O3" value="465"/>
                    <count group_id="O4" value="466"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="441"/>
                    <measurement group_id="O2" value="440"/>
                    <measurement group_id="O3" value="435"/>
                    <measurement group_id="O4" value="444"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5) Head, ears, eyes, nose, throat, neck (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="426"/>
                    <count group_id="O2" value="433"/>
                    <count group_id="O3" value="435"/>
                    <count group_id="O4" value="436"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="398"/>
                    <measurement group_id="O2" value="411"/>
                    <measurement group_id="O3" value="404"/>
                    <measurement group_id="O4" value="410"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5) Head, ears, eyes, nose, throat, neck (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="424"/>
                    <count group_id="O2" value="423"/>
                    <count group_id="O3" value="428"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="400"/>
                    <measurement group_id="O2" value="405"/>
                    <measurement group_id="O3" value="399"/>
                    <measurement group_id="O4" value="415"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6) Lymph node palpation (week -2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="466"/>
                    <count group_id="O2" value="463"/>
                    <count group_id="O3" value="465"/>
                    <count group_id="O4" value="466"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="466"/>
                    <measurement group_id="O2" value="462"/>
                    <measurement group_id="O3" value="463"/>
                    <measurement group_id="O4" value="464"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6) Lymph node palpation (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="426"/>
                    <count group_id="O2" value="433"/>
                    <count group_id="O3" value="435"/>
                    <count group_id="O4" value="436"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="425"/>
                    <measurement group_id="O2" value="432"/>
                    <measurement group_id="O3" value="434"/>
                    <measurement group_id="O4" value="436"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6) Lymph node palpation (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="423"/>
                    <count group_id="O2" value="423"/>
                    <count group_id="O3" value="428"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="421"/>
                    <measurement group_id="O2" value="423"/>
                    <measurement group_id="O3" value="425"/>
                    <measurement group_id="O4" value="441"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7) Musculoskeletal system (week -2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="466"/>
                    <count group_id="O2" value="464"/>
                    <count group_id="O3" value="465"/>
                    <count group_id="O4" value="466"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="421"/>
                    <measurement group_id="O2" value="435"/>
                    <measurement group_id="O3" value="440"/>
                    <measurement group_id="O4" value="430"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7) Musculoskeletal system (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="426"/>
                    <count group_id="O2" value="433"/>
                    <count group_id="O3" value="435"/>
                    <count group_id="O4" value="435"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="383"/>
                    <measurement group_id="O2" value="400"/>
                    <measurement group_id="O3" value="408"/>
                    <measurement group_id="O4" value="403"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7) Musculoskeletal system (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="424"/>
                    <count group_id="O2" value="423"/>
                    <count group_id="O3" value="428"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="388"/>
                    <measurement group_id="O2" value="389"/>
                    <measurement group_id="O3" value="402"/>
                    <measurement group_id="O4" value="413"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8) Respiratory system (week -2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="466"/>
                    <count group_id="O2" value="464"/>
                    <count group_id="O3" value="465"/>
                    <count group_id="O4" value="466"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="458"/>
                    <measurement group_id="O2" value="451"/>
                    <measurement group_id="O3" value="462"/>
                    <measurement group_id="O4" value="456"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8) Respiratory system (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="426"/>
                    <count group_id="O2" value="433"/>
                    <count group_id="O3" value="435"/>
                    <count group_id="O4" value="436"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="418"/>
                    <measurement group_id="O2" value="427"/>
                    <measurement group_id="O3" value="431"/>
                    <measurement group_id="O4" value="429"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8) Respiratory system (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="424"/>
                    <count group_id="O2" value="423"/>
                    <count group_id="O3" value="428"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="419"/>
                    <measurement group_id="O2" value="418"/>
                    <measurement group_id="O3" value="427"/>
                    <measurement group_id="O4" value="434"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9) Skin (week -2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="466"/>
                    <count group_id="O2" value="464"/>
                    <count group_id="O3" value="465"/>
                    <count group_id="O4" value="466"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="394"/>
                    <measurement group_id="O2" value="400"/>
                    <measurement group_id="O3" value="394"/>
                    <measurement group_id="O4" value="402"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9) Skin (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="427"/>
                    <count group_id="O2" value="433"/>
                    <count group_id="O3" value="435"/>
                    <count group_id="O4" value="436"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="372"/>
                    <measurement group_id="O2" value="383"/>
                    <measurement group_id="O3" value="383"/>
                    <measurement group_id="O4" value="375"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9) Skin (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="424"/>
                    <count group_id="O2" value="423"/>
                    <count group_id="O3" value="428"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="361"/>
                    <measurement group_id="O2" value="370"/>
                    <measurement group_id="O3" value="382"/>
                    <measurement group_id="O4" value="393"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10) Thyroid gland (week -2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="465"/>
                    <count group_id="O2" value="464"/>
                    <count group_id="O3" value="465"/>
                    <count group_id="O4" value="466"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="451"/>
                    <measurement group_id="O2" value="452"/>
                    <measurement group_id="O3" value="451"/>
                    <measurement group_id="O4" value="454"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10) Thyroid gland (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="426"/>
                    <count group_id="O2" value="433"/>
                    <count group_id="O3" value="435"/>
                    <count group_id="O4" value="436"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="413"/>
                    <measurement group_id="O2" value="423"/>
                    <measurement group_id="O3" value="425"/>
                    <measurement group_id="O4" value="427"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10) Thyroid gland (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="424"/>
                    <count group_id="O2" value="423"/>
                    <count group_id="O3" value="428"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="411"/>
                    <measurement group_id="O2" value="411"/>
                    <measurement group_id="O3" value="418"/>
                    <measurement group_id="O4" value="433"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Eye Examination Category</title>
        <description>Participants with eye examination (fundoscopy) findings, normal, abnormal NCS and abnormal CS at baseline (week -2), week 52 and week 78 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
        <time_frame>Week -2, week 52, week 78</time_frame>
        <population>Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Eye Examination Category</title>
          <description>Participants with eye examination (fundoscopy) findings, normal, abnormal NCS and abnormal CS at baseline (week -2), week 52 and week 78 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
          <population>Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product. Number Analyzed = number of participants with available data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="464"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Left eye (week -2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="459"/>
                    <count group_id="O2" value="455"/>
                    <count group_id="O3" value="457"/>
                    <count group_id="O4" value="463"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="302"/>
                    <measurement group_id="O2" value="299"/>
                    <measurement group_id="O3" value="305"/>
                    <measurement group_id="O4" value="297"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="138"/>
                    <measurement group_id="O3" value="129"/>
                    <measurement group_id="O4" value="137"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left eye (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="393"/>
                    <count group_id="O2" value="388"/>
                    <count group_id="O3" value="391"/>
                    <count group_id="O4" value="405"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="249"/>
                    <measurement group_id="O2" value="253"/>
                    <measurement group_id="O3" value="270"/>
                    <measurement group_id="O4" value="252"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="113"/>
                    <measurement group_id="O3" value="101"/>
                    <measurement group_id="O4" value="126"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left eye (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="417"/>
                    <count group_id="O2" value="415"/>
                    <count group_id="O3" value="420"/>
                    <count group_id="O4" value="431"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="261"/>
                    <measurement group_id="O2" value="255"/>
                    <measurement group_id="O3" value="273"/>
                    <measurement group_id="O4" value="287"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="141"/>
                    <measurement group_id="O3" value="130"/>
                    <measurement group_id="O4" value="113"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right eye (week -2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="459"/>
                    <count group_id="O2" value="454"/>
                    <count group_id="O3" value="457"/>
                    <count group_id="O4" value="463"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="309"/>
                    <measurement group_id="O2" value="298"/>
                    <measurement group_id="O3" value="308"/>
                    <measurement group_id="O4" value="297"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                    <measurement group_id="O2" value="139"/>
                    <measurement group_id="O3" value="126"/>
                    <measurement group_id="O4" value="138"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right eye (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="393"/>
                    <count group_id="O2" value="388"/>
                    <count group_id="O3" value="391"/>
                    <count group_id="O4" value="405"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="247"/>
                    <measurement group_id="O2" value="256"/>
                    <measurement group_id="O3" value="271"/>
                    <measurement group_id="O4" value="255"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="112"/>
                    <measurement group_id="O3" value="103"/>
                    <measurement group_id="O4" value="123"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right eye (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="417"/>
                    <count group_id="O2" value="415"/>
                    <count group_id="O3" value="420"/>
                    <count group_id="O4" value="431"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="258"/>
                    <measurement group_id="O2" value="255"/>
                    <measurement group_id="O3" value="275"/>
                    <measurement group_id="O4" value="279"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="146"/>
                    <measurement group_id="O3" value="128"/>
                    <measurement group_id="O4" value="122"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Anti-semaglutide Binding Antibodies (Yes/no)</title>
        <description>This outcome measure is only applicable for the oral semaglutide treatment arms (3 mg, 7 mg and 14 mg). Number of participants who measured with anti-semaglutide binding antibodies anytime during post-baseline visits (weeks 0-83) are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
        <time_frame>Weeks 0-83</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Anti-semaglutide Binding Antibodies (Yes/no)</title>
          <description>This outcome measure is only applicable for the oral semaglutide treatment arms (3 mg, 7 mg and 14 mg). Number of participants who measured with anti-semaglutide binding antibodies anytime during post-baseline visits (weeks 0-83) are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="459"/>
                <count group_id="O2" value="460"/>
                <count group_id="O3" value="465"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Anti-semaglutide Neutralising Antibodies (Yes/no)</title>
        <description>This outcome measure is only applicable for the oral semaglutide treatment arms (3 mg, 7 mg and 14 mg). Number of participants who measured with anti-semaglutide neutralising antibodies anytime during post-baseline visits (weeks 0-83) are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
        <time_frame>Weeks 0-83</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Anti-semaglutide Neutralising Antibodies (Yes/no)</title>
          <description>This outcome measure is only applicable for the oral semaglutide treatment arms (3 mg, 7 mg and 14 mg). Number of participants who measured with anti-semaglutide neutralising antibodies anytime during post-baseline visits (weeks 0-83) are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="459"/>
                <count group_id="O2" value="460"/>
                <count group_id="O3" value="465"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Anti-semaglutide Binding Antibodies Cross Reacting With Native GLP-1 (Yes/no)</title>
        <description>This outcome measure is only applicable for the oral semaglutide treatment arms (3 mg, 7 mg and 14 mg). Number of participants who measured with anti-semaglutide binding antibodies cross reacting with native glucagon-like peptide-1 (GLP-1) anytime during post-baseline visits (weeks 0-83) are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
        <time_frame>Weeks 0-83</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Anti-semaglutide Binding Antibodies Cross Reacting With Native GLP-1 (Yes/no)</title>
          <description>This outcome measure is only applicable for the oral semaglutide treatment arms (3 mg, 7 mg and 14 mg). Number of participants who measured with anti-semaglutide binding antibodies cross reacting with native glucagon-like peptide-1 (GLP-1) anytime during post-baseline visits (weeks 0-83) are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="459"/>
                <count group_id="O2" value="460"/>
                <count group_id="O3" value="465"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Anti-semaglutide Neutralising Antibodies Cross Reacting With Native GLP-1 (Yes/no)</title>
        <description>This outcome measure is only applicable for the oral semaglutide treatment arms (3 mg, 7 mg and 14 mg). Number of participants who measured with anti-semaglutide neutralising antibodies cross reacting with native GLP-1 anytime during post-baseline visits (weeks 0-83) are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
        <time_frame>Weeks 0-83</time_frame>
        <population>Overall number of participants analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Anti-semaglutide Neutralising Antibodies Cross Reacting With Native GLP-1 (Yes/no)</title>
          <description>This outcome measure is only applicable for the oral semaglutide treatment arms (3 mg, 7 mg and 14 mg). Number of participants who measured with anti-semaglutide neutralising antibodies cross reacting with native GLP-1 anytime during post-baseline visits (weeks 0-83) are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
          <population>Overall number of participants analyzed = number of participants with available data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="459"/>
                <count group_id="O2" value="460"/>
                <count group_id="O3" value="465"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-semaglutide Binding Antibody Levels</title>
        <description>This outcome measure is only applicable for the oral semaglutide treatment arms (3 mg, 7 mg and 14 mg). It is based on the data from participants who were measured with anti-semaglutide antibodies anytime during post-baseline visits (weeks 0-83). Results are presented as percentage of bound radioactivity-labelled semaglutide /total added radioactivity-labelled semaglutide (%B/T). Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
        <time_frame>Weeks 0-83</time_frame>
        <population>Overall number of participants analysed = participants who were found positive for anti-semaglutide antibodies.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-semaglutide Binding Antibody Levels</title>
          <description>This outcome measure is only applicable for the oral semaglutide treatment arms (3 mg, 7 mg and 14 mg). It is based on the data from participants who were measured with anti-semaglutide antibodies anytime during post-baseline visits (weeks 0-83). Results are presented as percentage of bound radioactivity-labelled semaglutide /total added radioactivity-labelled semaglutide (%B/T). Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
          <population>Overall number of participants analysed = participants who were found positive for anti-semaglutide antibodies.</population>
          <units>%B/T</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="9.82" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="3.28" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2.39" spread="0"/>
                    <measurement group_id="O3" value="2.05" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 38</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="2.24" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Week 83</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Treatment-emergent Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes</title>
        <description>Treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes were recorded during weeks 0-83 (78-week treatment period plus the 5-week follow-up period). Hypoglycaemic episodes with onset during the on-treatment observation period were considered treatment-emergent. On-treatment observation period was defined as the time period when a subject was on treatment with trial product, including any period after initiation of rescue medication. Severe hypoglycaemia was defined as an episode requiring assistance of another person to actively administer carbohydrate or glucagon, or take other corrective actions. BG-confirmed symptomatic hypoglycaemia: Confirmed by a glucose value &lt;3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.</description>
        <time_frame>Weeks 0-83</time_frame>
        <population>Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Treatment-emergent Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes</title>
          <description>Treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes were recorded during weeks 0-83 (78-week treatment period plus the 5-week follow-up period). Hypoglycaemic episodes with onset during the on-treatment observation period were considered treatment-emergent. On-treatment observation period was defined as the time period when a subject was on treatment with trial product, including any period after initiation of rescue medication. Severe hypoglycaemia was defined as an episode requiring assistance of another person to actively administer carbohydrate or glucagon, or take other corrective actions. BG-confirmed symptomatic hypoglycaemia: Confirmed by a glucose value &lt;3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.</description>
          <population>Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product.</population>
          <units>Episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="464"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="60"/>
                    <measurement group_id="O4" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Treatment-emergent Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes</title>
        <description>Treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes were recorded from week 0 to week 83 (78-week treatment period plus the 5-week follow-up period). Hypoglycaemic episodes with onset during the on-treatment observation period were considered treatment-emergent. On-treatment observation period was defined as the time period when a subject was on treatment with trial product, including any period after initiation of rescue medication. Severe hypoglycaemia was defined as an episode requiring assistance of another person to actively administer carbohydrate or glucagon, or take other corrective actions. BG-confirmed symptomatic hypoglycaemia: Confirmed by a glucose value &lt;3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.</description>
        <time_frame>Weeks 0-83</time_frame>
        <population>Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Treatment-emergent Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes</title>
          <description>Treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes were recorded from week 0 to week 83 (78-week treatment period plus the 5-week follow-up period). Hypoglycaemic episodes with onset during the on-treatment observation period were considered treatment-emergent. On-treatment observation period was defined as the time period when a subject was on treatment with trial product, including any period after initiation of rescue medication. Severe hypoglycaemia was defined as an episode requiring assistance of another person to actively administer carbohydrate or glucagon, or take other corrective actions. BG-confirmed symptomatic hypoglycaemia: Confirmed by a glucose value &lt;3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.</description>
          <population>Overall number of participants analyzed = SAS which comprised all randomised participants who received at least one dose of trial product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="464"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Semaglutide Plasma Concentration in a Subset of the Participants for Population PK Analyses</title>
        <description>This outcome measure is only applicable for the oral semaglutide treatment arms (3 mg, 7 mg and 14 mg). Semaglutide plasma concentrations for participants in the pharmacokinetic (PK) subpopulation are presented. The PK subpopulation consisted of participants from sites in Germany, Japan and the United States receiving oral semaglutide (3 mg, 7 mg or 14 mg). Results are based on the data from the on-treatment observation period and follow-up period. The on-treatment observation period was the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.</description>
        <time_frame>Weeks 0-83</time_frame>
        <population>Overall number of participants analysed = number of participants in the PK subpopulation. Number Analyzed = number of participants with available data in the PK subpopulation.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Semaglutide Plasma Concentration in a Subset of the Participants for Population PK Analyses</title>
          <description>This outcome measure is only applicable for the oral semaglutide treatment arms (3 mg, 7 mg and 14 mg). Semaglutide plasma concentrations for participants in the pharmacokinetic (PK) subpopulation are presented. The PK subpopulation consisted of participants from sites in Germany, Japan and the United States receiving oral semaglutide (3 mg, 7 mg or 14 mg). Results are based on the data from the on-treatment observation period and follow-up period. The on-treatment observation period was the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication.</description>
          <population>Overall number of participants analysed = number of participants in the PK subpopulation. Number Analyzed = number of participants with available data in the PK subpopulation.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="215"/>
                <count group_id="O3" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="187"/>
                    <count group_id="O3" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.0"/>
                    <measurement group_id="O2" value="0.4" spread="0.0"/>
                    <measurement group_id="O3" value="0.4" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="212"/>
                    <count group_id="O2" value="208"/>
                    <count group_id="O3" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="109.3"/>
                    <measurement group_id="O2" value="1.5" spread="102.1"/>
                    <measurement group_id="O3" value="1.6" spread="109.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="208"/>
                    <count group_id="O2" value="198"/>
                    <count group_id="O3" value="190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="103.9"/>
                    <measurement group_id="O2" value="4.1" spread="129.4"/>
                    <measurement group_id="O3" value="4.2" spread="128.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="201"/>
                    <count group_id="O2" value="190"/>
                    <count group_id="O3" value="185"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="111.8"/>
                    <measurement group_id="O2" value="4.0" spread="146.8"/>
                    <measurement group_id="O3" value="9.4" spread="156.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="190"/>
                    <count group_id="O3" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="104.5"/>
                    <measurement group_id="O2" value="3.7" spread="122.5"/>
                    <measurement group_id="O3" value="8.6" spread="162.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 38</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="183"/>
                    <count group_id="O2" value="180"/>
                    <count group_id="O3" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="107.8"/>
                    <measurement group_id="O2" value="3.5" spread="106.4"/>
                    <measurement group_id="O3" value="8.6" spread="163.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="178"/>
                    <count group_id="O3" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="105.8"/>
                    <measurement group_id="O2" value="3.5" spread="119.0"/>
                    <measurement group_id="O3" value="8.2" spread="167.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="167"/>
                    <count group_id="O2" value="173"/>
                    <count group_id="O3" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="115.3"/>
                    <measurement group_id="O2" value="3.5" spread="127.2"/>
                    <measurement group_id="O3" value="8.9" spread="152.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 83</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="172"/>
                    <count group_id="O3" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="10.3"/>
                    <measurement group_id="O2" value="0.4" spread="16.5"/>
                    <measurement group_id="O3" value="0.4" spread="42.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in SF-36v2 (Acute Version) Health Survey: Scores From the 8 Domains, the Physical Component Summary (PCS) and the Mental Component Summary (MCS)</title>
        <description>SF-36 is a 36-item patient-reported survey of patient health that measures the participant's overall health-related quality of life (HRQoL). SF-36v2™ (acute version) questionnaire measured eight domains of functional health and well-being as well as two component summary scores (physical component summary (PCS) and mental component summary (MCS)). The 0-100 scale scores (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. In the metric of norm-based scores, 50 and 10 corresponds to the mean and standard deviation respectively of the 2009 U.S. general population. Change from baseline (week 0) in the domain scores and component summary (PCS and MCS) scores were evaluated at weeks 26, 52 and 78. A positive change score indicates an improvement since baseline. Results are based on the data from the in-trial observation period.</description>
        <time_frame>Week 0, week 26, week 52, week 78</time_frame>
        <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in SF-36v2 (Acute Version) Health Survey: Scores From the 8 Domains, the Physical Component Summary (PCS) and the Mental Component Summary (MCS)</title>
          <description>SF-36 is a 36-item patient-reported survey of patient health that measures the participant's overall health-related quality of life (HRQoL). SF-36v2™ (acute version) questionnaire measured eight domains of functional health and well-being as well as two component summary scores (physical component summary (PCS) and mental component summary (MCS)). The 0-100 scale scores (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. In the metric of norm-based scores, 50 and 10 corresponds to the mean and standard deviation respectively of the 2009 U.S. general population. Change from baseline (week 0) in the domain scores and component summary (PCS and MCS) scores were evaluated at weeks 26, 52 and 78. A positive change score indicates an improvement since baseline. Results are based on the data from the in-trial observation period.</description>
          <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="465"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1) Physical functioning (week 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="438"/>
                    <count group_id="O3" value="437"/>
                    <count group_id="O4" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="7.25"/>
                    <measurement group_id="O2" value="1.12" spread="6.52"/>
                    <measurement group_id="O3" value="0.63" spread="7.13"/>
                    <measurement group_id="O4" value="0.46" spread="6.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1) Physical functioning (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="433"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="437"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="7.14"/>
                    <measurement group_id="O2" value="0.64" spread="7.34"/>
                    <measurement group_id="O3" value="0.36" spread="7.30"/>
                    <measurement group_id="O4" value="0.06" spread="7.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1) Physical functioning (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="424"/>
                    <count group_id="O3" value="427"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="8.09"/>
                    <measurement group_id="O2" value="0.94" spread="6.91"/>
                    <measurement group_id="O3" value="0.54" spread="7.98"/>
                    <measurement group_id="O4" value="0.09" spread="7.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2) Role-Physical (week 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="438"/>
                    <count group_id="O3" value="437"/>
                    <count group_id="O4" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="7.85"/>
                    <measurement group_id="O2" value="0.76" spread="7.15"/>
                    <measurement group_id="O3" value="-0.13" spread="7.59"/>
                    <measurement group_id="O4" value="0.38" spread="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2) Role-Physical (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="433"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="437"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="8.40"/>
                    <measurement group_id="O2" value="-0.06" spread="9.42"/>
                    <measurement group_id="O3" value="-0.82" spread="8.49"/>
                    <measurement group_id="O4" value="-0.69" spread="8.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2) Role-Physical (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="424"/>
                    <count group_id="O3" value="427"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="8.14"/>
                    <measurement group_id="O2" value="-0.01" spread="8.40"/>
                    <measurement group_id="O3" value="-0.33" spread="7.57"/>
                    <measurement group_id="O4" value="0.44" spread="7.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3) Bodily pain (week 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="438"/>
                    <count group_id="O3" value="437"/>
                    <count group_id="O4" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="9.20"/>
                    <measurement group_id="O2" value="-0.11" spread="8.60"/>
                    <measurement group_id="O3" value="0.22" spread="9.02"/>
                    <measurement group_id="O4" value="0.44" spread="9.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3) Bodily pain (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="433"/>
                    <count group_id="O3" value="433"/>
                    <count group_id="O4" value="437"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="9.44"/>
                    <measurement group_id="O2" value="-0.65" spread="9.92"/>
                    <measurement group_id="O3" value="-0.64" spread="9.40"/>
                    <measurement group_id="O4" value="0.67" spread="8.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3) Bodily pain (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="424"/>
                    <count group_id="O3" value="427"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="9.24"/>
                    <measurement group_id="O2" value="0.32" spread="8.85"/>
                    <measurement group_id="O3" value="0.74" spread="9.40"/>
                    <measurement group_id="O4" value="0.54" spread="9.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4) General health (week 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="438"/>
                    <count group_id="O3" value="437"/>
                    <count group_id="O4" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" spread="6.50"/>
                    <measurement group_id="O2" value="1.67" spread="6.98"/>
                    <measurement group_id="O3" value="1.19" spread="7.00"/>
                    <measurement group_id="O4" value="1.42" spread="7.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4) General health (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="433"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="437"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="7.07"/>
                    <measurement group_id="O2" value="1.20" spread="7.08"/>
                    <measurement group_id="O3" value="1.03" spread="6.88"/>
                    <measurement group_id="O4" value="0.95" spread="7.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4) General health (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="424"/>
                    <count group_id="O3" value="427"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" spread="7.23"/>
                    <measurement group_id="O2" value="1.21" spread="7.60"/>
                    <measurement group_id="O3" value="1.21" spread="7.62"/>
                    <measurement group_id="O4" value="1.32" spread="7.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5) Vitality (week 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="438"/>
                    <count group_id="O3" value="437"/>
                    <count group_id="O4" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59" spread="7.28"/>
                    <measurement group_id="O2" value="1.11" spread="7.30"/>
                    <measurement group_id="O3" value="0.88" spread="7.42"/>
                    <measurement group_id="O4" value="1.03" spread="7.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5) Vitality (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="433"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="437"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="7.50"/>
                    <measurement group_id="O2" value="0.79" spread="8.33"/>
                    <measurement group_id="O3" value="0.58" spread="8.15"/>
                    <measurement group_id="O4" value="0.19" spread="7.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5) Vitality (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="424"/>
                    <count group_id="O3" value="427"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="8.06"/>
                    <measurement group_id="O2" value="0.85" spread="7.92"/>
                    <measurement group_id="O3" value="0.71" spread="8.42"/>
                    <measurement group_id="O4" value="1.07" spread="8.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6) Social functioning (week 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="438"/>
                    <count group_id="O3" value="437"/>
                    <count group_id="O4" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="7.93"/>
                    <measurement group_id="O2" value="0.15" spread="8.03"/>
                    <measurement group_id="O3" value="0.31" spread="7.33"/>
                    <measurement group_id="O4" value="0.09" spread="8.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6) Social functioning (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="433"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="437"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="8.35"/>
                    <measurement group_id="O2" value="-0.37" spread="9.39"/>
                    <measurement group_id="O3" value="-0.83" spread="8.83"/>
                    <measurement group_id="O4" value="-0.68" spread="9.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6) Social functioning (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="424"/>
                    <count group_id="O3" value="427"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="8.29"/>
                    <measurement group_id="O2" value="0.19" spread="8.77"/>
                    <measurement group_id="O3" value="-0.27" spread="8.66"/>
                    <measurement group_id="O4" value="0.57" spread="8.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7) Role emotional (week 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="438"/>
                    <count group_id="O3" value="437"/>
                    <count group_id="O4" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" spread="10.47"/>
                    <measurement group_id="O2" value="0.67" spread="9.18"/>
                    <measurement group_id="O3" value="-0.37" spread="9.77"/>
                    <measurement group_id="O4" value="0.15" spread="9.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7) Role emotional (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="433"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="437"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="10.99"/>
                    <measurement group_id="O2" value="-0.45" spread="11.89"/>
                    <measurement group_id="O3" value="-0.86" spread="10.65"/>
                    <measurement group_id="O4" value="-0.63" spread="10.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7) Role emotional (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="424"/>
                    <count group_id="O2" value="424"/>
                    <count group_id="O3" value="427"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="10.98"/>
                    <measurement group_id="O2" value="0.23" spread="10.95"/>
                    <measurement group_id="O3" value="-0.30" spread="11.00"/>
                    <measurement group_id="O4" value="-0.24" spread="10.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8) Mental health (week 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="438"/>
                    <count group_id="O3" value="437"/>
                    <count group_id="O4" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="8.32"/>
                    <measurement group_id="O2" value="0.24" spread="8.17"/>
                    <measurement group_id="O3" value="0.24" spread="8.14"/>
                    <measurement group_id="O4" value="0.61" spread="8.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8) Mental health (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="433"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="437"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="8.02"/>
                    <measurement group_id="O2" value="0.42" spread="9.11"/>
                    <measurement group_id="O3" value="0.05" spread="7.99"/>
                    <measurement group_id="O4" value="0.23" spread="8.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8) Mental health (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="424"/>
                    <count group_id="O3" value="427"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="9.08"/>
                    <measurement group_id="O2" value="0.29" spread="9.33"/>
                    <measurement group_id="O3" value="0.28" spread="8.87"/>
                    <measurement group_id="O4" value="0.30" spread="9.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical component summary (week 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="438"/>
                    <count group_id="O3" value="437"/>
                    <count group_id="O4" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="6.42"/>
                    <measurement group_id="O2" value="0.98" spread="5.72"/>
                    <measurement group_id="O3" value="0.63" spread="6.00"/>
                    <measurement group_id="O4" value="0.69" spread="6.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical component summary (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="433"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="437"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="6.50"/>
                    <measurement group_id="O2" value="0.36" spread="6.82"/>
                    <measurement group_id="O3" value="0.09" spread="6.47"/>
                    <measurement group_id="O4" value="0.31" spread="6.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical component summary (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="424"/>
                    <count group_id="O3" value="427"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="6.74"/>
                    <measurement group_id="O2" value="0.71" spread="6.24"/>
                    <measurement group_id="O3" value="0.67" spread="6.29"/>
                    <measurement group_id="O4" value="0.70" spread="6.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental component summary (week 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="438"/>
                    <count group_id="O3" value="437"/>
                    <count group_id="O4" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="8.62"/>
                    <measurement group_id="O2" value="0.34" spread="8.26"/>
                    <measurement group_id="O3" value="0.08" spread="8.18"/>
                    <measurement group_id="O4" value="0.41" spread="8.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental component summary (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="433"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="437"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="8.41"/>
                    <measurement group_id="O2" value="-0.00" spread="9.43"/>
                    <measurement group_id="O3" value="-0.37" spread="8.64"/>
                    <measurement group_id="O4" value="-0.31" spread="8.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental component summary (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="424"/>
                    <count group_id="O3" value="427"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="9.18"/>
                    <measurement group_id="O2" value="0.23" spread="9.50"/>
                    <measurement group_id="O3" value="-0.07" spread="9.31"/>
                    <measurement group_id="O4" value="0.30" spread="9.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in IWQoL-Lite-CT: Total Score and Scores From the 4 Domains</title>
        <description>The Impact of Weight on Quality of Life Clinical Trials Version (IWQOL-Lite-CT) is designed to assess the impact of changes in weight on patients' quality of life within the context of clinical trials. The items of the IWQOL-Lite-CT pertain to physical functioning (physical, physical function and pain/discomfort) and psychosocial domains and all items employ a 5-point graded response scale (never, rarely, sometimes, usually, always; or not at all true, a little true, moderately true, mostly true, completely true). All IWQOL-Lite-CT composite scores range from 0 to 100, with higher scores reflecting better levels of functioning. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
        <time_frame>Week 0, week 26, week 52, week 78</time_frame>
        <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IWQoL-Lite-CT: Total Score and Scores From the 4 Domains</title>
          <description>The Impact of Weight on Quality of Life Clinical Trials Version (IWQOL-Lite-CT) is designed to assess the impact of changes in weight on patients' quality of life within the context of clinical trials. The items of the IWQOL-Lite-CT pertain to physical functioning (physical, physical function and pain/discomfort) and psychosocial domains and all items employ a 5-point graded response scale (never, rarely, sometimes, usually, always; or not at all true, a little true, moderately true, mostly true, completely true). All IWQOL-Lite-CT composite scores range from 0 to 100, with higher scores reflecting better levels of functioning. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</description>
          <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="465"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1) Physical (week 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="437"/>
                    <count group_id="O3" value="437"/>
                    <count group_id="O4" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.25" spread="14.81"/>
                    <measurement group_id="O2" value="2.38" spread="14.87"/>
                    <measurement group_id="O3" value="2.87" spread="17.32"/>
                    <measurement group_id="O4" value="1.97" spread="15.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1) Physical (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="432"/>
                    <count group_id="O3" value="433"/>
                    <count group_id="O4" value="437"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.84" spread="15.80"/>
                    <measurement group_id="O2" value="3.03" spread="16.32"/>
                    <measurement group_id="O3" value="3.18" spread="18.40"/>
                    <measurement group_id="O4" value="1.49" spread="16.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1) Physical (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="425"/>
                    <count group_id="O3" value="427"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.71" spread="16.16"/>
                    <measurement group_id="O2" value="3.55" spread="16.47"/>
                    <measurement group_id="O3" value="3.86" spread="17.37"/>
                    <measurement group_id="O4" value="2.86" spread="17.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2) Physical function (week 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="437"/>
                    <count group_id="O3" value="437"/>
                    <count group_id="O4" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.52" spread="16.48"/>
                    <measurement group_id="O2" value="2.78" spread="16.13"/>
                    <measurement group_id="O3" value="3.20" spread="18.48"/>
                    <measurement group_id="O4" value="1.70" spread="16.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2) Physical function (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="432"/>
                    <count group_id="O3" value="433"/>
                    <count group_id="O4" value="437"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.28" spread="17.00"/>
                    <measurement group_id="O2" value="3.24" spread="18.17"/>
                    <measurement group_id="O3" value="3.19" spread="19.76"/>
                    <measurement group_id="O4" value="1.22" spread="18.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2) Physical function (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="425"/>
                    <count group_id="O3" value="427"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.55" spread="17.86"/>
                    <measurement group_id="O2" value="4.04" spread="17.99"/>
                    <measurement group_id="O3" value="3.76" spread="18.78"/>
                    <measurement group_id="O4" value="2.54" spread="18.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3) Pain/discomfort (week 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="437"/>
                    <count group_id="O3" value="437"/>
                    <count group_id="O4" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.51" spread="20.28"/>
                    <measurement group_id="O2" value="1.37" spread="21.34"/>
                    <measurement group_id="O3" value="2.03" spread="22.10"/>
                    <measurement group_id="O4" value="2.66" spread="21.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3) Pain/discomfort (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="432"/>
                    <count group_id="O3" value="433"/>
                    <count group_id="O4" value="437"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="22.31"/>
                    <measurement group_id="O2" value="2.52" spread="22.04"/>
                    <measurement group_id="O3" value="3.15" spread="23.29"/>
                    <measurement group_id="O4" value="2.12" spread="21.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3) Pain/discomfort (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="425"/>
                    <count group_id="O3" value="427"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.06" spread="20.39"/>
                    <measurement group_id="O2" value="2.35" spread="22.66"/>
                    <measurement group_id="O3" value="4.07" spread="22.28"/>
                    <measurement group_id="O4" value="3.63" spread="22.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4) Psychosocial (week 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="437"/>
                    <count group_id="O3" value="437"/>
                    <count group_id="O4" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.69" spread="13.32"/>
                    <measurement group_id="O2" value="4.30" spread="15.05"/>
                    <measurement group_id="O3" value="2.98" spread="14.86"/>
                    <measurement group_id="O4" value="2.10" spread="13.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4) Psychosocial (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="432"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="437"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.12" spread="14.55"/>
                    <measurement group_id="O2" value="5.19" spread="15.04"/>
                    <measurement group_id="O3" value="3.97" spread="16.46"/>
                    <measurement group_id="O4" value="2.53" spread="14.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4) Psychosocial (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="424"/>
                    <count group_id="O2" value="425"/>
                    <count group_id="O3" value="427"/>
                    <count group_id="O4" value="440"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.83" spread="14.89"/>
                    <measurement group_id="O2" value="5.36" spread="15.62"/>
                    <measurement group_id="O3" value="3.73" spread="16.22"/>
                    <measurement group_id="O4" value="3.29" spread="14.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IWQOL-Lite-CT Total (week 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="437"/>
                    <count group_id="O3" value="437"/>
                    <count group_id="O4" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.88" spread="12.11"/>
                    <measurement group_id="O2" value="3.62" spread="13.37"/>
                    <measurement group_id="O3" value="2.95" spread="13.87"/>
                    <measurement group_id="O4" value="2.05" spread="12.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IWQOL-Lite-CT Total (week 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="432"/>
                    <count group_id="O3" value="433"/>
                    <count group_id="O4" value="437"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.67" spread="13.01"/>
                    <measurement group_id="O2" value="4.43" spread="13.59"/>
                    <measurement group_id="O3" value="3.64" spread="15.22"/>
                    <measurement group_id="O4" value="2.17" spread="12.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IWQOL-Lite-CT Total (week 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="424"/>
                    <count group_id="O2" value="425"/>
                    <count group_id="O3" value="427"/>
                    <count group_id="O4" value="440"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.45" spread="13.32"/>
                    <measurement group_id="O2" value="4.73" spread="14.07"/>
                    <measurement group_id="O3" value="3.77" spread="14.97"/>
                    <measurement group_id="O4" value="3.16" spread="13.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CoEQ: Scores From the 4 Domains and the 19 Items</title>
        <description>Change from baseline (week 0) in Control of Eating Questionnaire (CoEQ) was evaluated at weeks (wk) 26, 52 and 78. The CoEQ comprised 19 items to assess the intensity and type of food cravings, as well as subjective sensation of appetite and mood, with the 4 domains: 'craving control' (items 9-12, 19), 'positive mood' (items 5-8), 'craving for savoury' (items 4, 16-18) and 'craving for sweet' (items 3, 13-15). The 19 items were scored on an 11-point graded response scale ranging from 10 to 0, with items relating to each of the 4 domains being averaged to create a final score. A low score in the domains 'craving for sweet and 'craving for savoury' represents a low level of craving; whereas a high score in the domains 'craving control' and 'positive mood' represents good control and a good mood, respectively. Results are based on the data from the in-trial observation period.</description>
        <time_frame>Week 0, week 26, week 52, week 78</time_frame>
        <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Semaglutide 3 mg</title>
            <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O2">
            <title>Oral Semaglutide 7 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O3">
            <title>Oral Semaglutide 14 mg</title>
            <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CoEQ: Scores From the 4 Domains and the 19 Items</title>
          <description>Change from baseline (week 0) in Control of Eating Questionnaire (CoEQ) was evaluated at weeks (wk) 26, 52 and 78. The CoEQ comprised 19 items to assess the intensity and type of food cravings, as well as subjective sensation of appetite and mood, with the 4 domains: 'craving control' (items 9-12, 19), 'positive mood' (items 5-8), 'craving for savoury' (items 4, 16-18) and 'craving for sweet' (items 3, 13-15). The 19 items were scored on an 11-point graded response scale ranging from 10 to 0, with items relating to each of the 4 domains being averaged to create a final score. A low score in the domains 'craving for sweet and 'craving for savoury' represents a low level of craving; whereas a high score in the domains 'craving control' and 'positive mood' represents good control and a good mood, respectively. Results are based on the data from the in-trial observation period.</description>
          <population>Overall number of participants analyzed = FAS which comprised all randomised participants. Number Analyzed = number of participants with available data.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
                <count group_id="O2" value="465"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1) Feeling of hunger (wk 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="435"/>
                    <count group_id="O3" value="437"/>
                    <count group_id="O4" value="446"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="2.61"/>
                    <measurement group_id="O2" value="-0.37" spread="2.58"/>
                    <measurement group_id="O3" value="-0.54" spread="2.58"/>
                    <measurement group_id="O4" value="-0.18" spread="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1) Feeling of hunger (wk 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="431"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="435"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="2.50"/>
                    <measurement group_id="O2" value="-0.23" spread="2.69"/>
                    <measurement group_id="O3" value="-0.35" spread="2.65"/>
                    <measurement group_id="O4" value="-0.25" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1) Feeling of hunger (wk 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="424"/>
                    <count group_id="O2" value="423"/>
                    <count group_id="O3" value="427"/>
                    <count group_id="O4" value="440"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="2.56"/>
                    <measurement group_id="O2" value="-0.22" spread="2.73"/>
                    <measurement group_id="O3" value="-0.36" spread="2.52"/>
                    <measurement group_id="O4" value="-0.22" spread="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2) Feeling of fullness (wk 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="435"/>
                    <count group_id="O3" value="436"/>
                    <count group_id="O4" value="446"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="2.66"/>
                    <measurement group_id="O2" value="-0.08" spread="2.77"/>
                    <measurement group_id="O3" value="0.15" spread="2.66"/>
                    <measurement group_id="O4" value="0.15" spread="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2) Feeling of fullness (wk 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="431"/>
                    <count group_id="O3" value="433"/>
                    <count group_id="O4" value="435"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="2.61"/>
                    <measurement group_id="O2" value="-0.07" spread="2.64"/>
                    <measurement group_id="O3" value="0.22" spread="2.68"/>
                    <measurement group_id="O4" value="0.27" spread="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2) Feeling of fullness (wk 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="423"/>
                    <count group_id="O3" value="426"/>
                    <count group_id="O4" value="440"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="2.59"/>
                    <measurement group_id="O2" value="-0.09" spread="2.71"/>
                    <measurement group_id="O3" value="0.09" spread="2.74"/>
                    <measurement group_id="O4" value="0.26" spread="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3) Desire to eat sweet foods (wk 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="435"/>
                    <count group_id="O3" value="437"/>
                    <count group_id="O4" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="2.55"/>
                    <measurement group_id="O2" value="-0.54" spread="3.02"/>
                    <measurement group_id="O3" value="-0.47" spread="2.98"/>
                    <measurement group_id="O4" value="-0.33" spread="2.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3) Desire to eat sweet foods (wk 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="431"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="435"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="2.74"/>
                    <measurement group_id="O2" value="-0.31" spread="2.97"/>
                    <measurement group_id="O3" value="-0.31" spread="3.02"/>
                    <measurement group_id="O4" value="-0.45" spread="2.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3) Desire to eat sweet foods (wk 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="424"/>
                    <count group_id="O3" value="427"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="2.51"/>
                    <measurement group_id="O2" value="-0.42" spread="3.02"/>
                    <measurement group_id="O3" value="-0.45" spread="2.97"/>
                    <measurement group_id="O4" value="-0.49" spread="2.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4) Desire to eat savoury foods (wk 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="434"/>
                    <count group_id="O3" value="437"/>
                    <count group_id="O4" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="2.48"/>
                    <measurement group_id="O2" value="-0.16" spread="2.88"/>
                    <measurement group_id="O3" value="-0.30" spread="3.03"/>
                    <measurement group_id="O4" value="-0.35" spread="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4) Desire to eat savoury foods (wk 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="431"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="436"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="2.78"/>
                    <measurement group_id="O2" value="-0.21" spread="2.80"/>
                    <measurement group_id="O3" value="-0.44" spread="2.94"/>
                    <measurement group_id="O4" value="-0.33" spread="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4) Desire to eat savoury foods (wk 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="424"/>
                    <count group_id="O3" value="427"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="2.64"/>
                    <measurement group_id="O2" value="-0.39" spread="2.95"/>
                    <measurement group_id="O3" value="-0.39" spread="2.80"/>
                    <measurement group_id="O4" value="-0.42" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5) Feeling of happiness (wk 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="434"/>
                    <count group_id="O3" value="435"/>
                    <count group_id="O4" value="446"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="2.22"/>
                    <measurement group_id="O2" value="0.03" spread="2.11"/>
                    <measurement group_id="O3" value="0.04" spread="2.22"/>
                    <measurement group_id="O4" value="0.13" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5) Feeling of happiness (wk 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="431"/>
                    <count group_id="O3" value="433"/>
                    <count group_id="O4" value="435"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="2.25"/>
                    <measurement group_id="O2" value="0.04" spread="2.21"/>
                    <measurement group_id="O3" value="0.09" spread="2.15"/>
                    <measurement group_id="O4" value="0.14" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5) Feeling of happiness (wk 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="424"/>
                    <count group_id="O3" value="426"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="2.32"/>
                    <measurement group_id="O2" value="-0.08" spread="2.21"/>
                    <measurement group_id="O3" value="0.04" spread="2.27"/>
                    <measurement group_id="O4" value="0.02" spread="2.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6) Feeling of anxiousness (wk 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="437"/>
                    <count group_id="O2" value="435"/>
                    <count group_id="O3" value="437"/>
                    <count group_id="O4" value="444"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="2.86"/>
                    <measurement group_id="O2" value="-0.18" spread="2.96"/>
                    <measurement group_id="O3" value="0.20" spread="3.22"/>
                    <measurement group_id="O4" value="-0.21" spread="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6) Feeling of anxiousness (wk 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="430"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="436"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="2.59"/>
                    <measurement group_id="O2" value="-0.16" spread="2.97"/>
                    <measurement group_id="O3" value="-0.06" spread="3.02"/>
                    <measurement group_id="O4" value="0.17" spread="3.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6) Feeling of anxiousness (wk 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="424"/>
                    <count group_id="O2" value="423"/>
                    <count group_id="O3" value="427"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="2.69"/>
                    <measurement group_id="O2" value="0.12" spread="3.22"/>
                    <measurement group_id="O3" value="-0.12" spread="2.88"/>
                    <measurement group_id="O4" value="-0.01" spread="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7) Feeling of alertness (wk 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="437"/>
                    <count group_id="O2" value="435"/>
                    <count group_id="O3" value="437"/>
                    <count group_id="O4" value="445"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="2.44"/>
                    <measurement group_id="O2" value="0.03" spread="2.61"/>
                    <measurement group_id="O3" value="-0.06" spread="2.49"/>
                    <measurement group_id="O4" value="0.05" spread="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7) Feeling of alertness (wk 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="431"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="435"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="2.52"/>
                    <measurement group_id="O2" value="-0.14" spread="2.87"/>
                    <measurement group_id="O3" value="-0.05" spread="2.50"/>
                    <measurement group_id="O4" value="-0.05" spread="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7) Feeling of alertness (wk 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="423"/>
                    <count group_id="O2" value="424"/>
                    <count group_id="O3" value="426"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="2.43"/>
                    <measurement group_id="O2" value="-0.04" spread="2.69"/>
                    <measurement group_id="O3" value="0.04" spread="2.48"/>
                    <measurement group_id="O4" value="-0.01" spread="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8) Feeling of contentment (wk 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="435"/>
                    <count group_id="O3" value="437"/>
                    <count group_id="O4" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="2.37"/>
                    <measurement group_id="O2" value="0.04" spread="2.38"/>
                    <measurement group_id="O3" value="0.18" spread="2.37"/>
                    <measurement group_id="O4" value="0.18" spread="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8) Feeling of contentment (wk 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="431"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="436"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="2.35"/>
                    <measurement group_id="O2" value="0.08" spread="2.48"/>
                    <measurement group_id="O3" value="0.13" spread="2.40"/>
                    <measurement group_id="O4" value="0.20" spread="2.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8) Feeling of contentment (wk 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="424"/>
                    <count group_id="O3" value="427"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="2.50"/>
                    <measurement group_id="O2" value="-0.03" spread="2.41"/>
                    <measurement group_id="O3" value="0.17" spread="2.38"/>
                    <measurement group_id="O4" value="0.17" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9) Food cravings during last 7 days (wk 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="437"/>
                    <count group_id="O2" value="433"/>
                    <count group_id="O3" value="437"/>
                    <count group_id="O4" value="445"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="2.87"/>
                    <measurement group_id="O2" value="-0.41" spread="2.94"/>
                    <measurement group_id="O3" value="-0.37" spread="2.69"/>
                    <measurement group_id="O4" value="-0.46" spread="2.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9) Food cravings during last 7 days (wk 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="431"/>
                    <count group_id="O3" value="433"/>
                    <count group_id="O4" value="435"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="2.99"/>
                    <measurement group_id="O2" value="-0.30" spread="2.96"/>
                    <measurement group_id="O3" value="-0.25" spread="2.86"/>
                    <measurement group_id="O4" value="-0.21" spread="3.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9) Food cravings during last 7 days (wk 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="423"/>
                    <count group_id="O2" value="423"/>
                    <count group_id="O3" value="427"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="2.87"/>
                    <measurement group_id="O2" value="-0.28" spread="2.90"/>
                    <measurement group_id="O3" value="-0.38" spread="2.91"/>
                    <measurement group_id="O4" value="-0.33" spread="3.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10) Strength of food cravings (wk 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="436"/>
                    <count group_id="O3" value="436"/>
                    <count group_id="O4" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" spread="2.75"/>
                    <measurement group_id="O2" value="-0.33" spread="2.93"/>
                    <measurement group_id="O3" value="-0.25" spread="2.79"/>
                    <measurement group_id="O4" value="-0.35" spread="2.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10) Strength of food cravings (wk 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="432"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="436"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="2.84"/>
                    <measurement group_id="O2" value="-0.14" spread="2.90"/>
                    <measurement group_id="O3" value="-0.21" spread="2.74"/>
                    <measurement group_id="O4" value="-0.30" spread="2.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10) Strength of food cravings (wk 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="425"/>
                    <count group_id="O3" value="427"/>
                    <count group_id="O4" value="439"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="2.89"/>
                    <measurement group_id="O2" value="-0.28" spread="2.99"/>
                    <measurement group_id="O3" value="-0.32" spread="2.85"/>
                    <measurement group_id="O4" value="-0.38" spread="2.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11) Difficulty to resist food cravings (wk 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="436"/>
                    <count group_id="O3" value="437"/>
                    <count group_id="O4" value="446"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="2.74"/>
                    <measurement group_id="O2" value="-0.38" spread="3.02"/>
                    <measurement group_id="O3" value="-0.46" spread="3.04"/>
                    <measurement group_id="O4" value="-0.17" spread="2.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11) Difficulty to resist food cravings (wk 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="431"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="436"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="2.79"/>
                    <measurement group_id="O2" value="-0.23" spread="3.04"/>
                    <measurement group_id="O3" value="-0.42" spread="3.16"/>
                    <measurement group_id="O4" value="-0.26" spread="3.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11) Difficulty to resist food cravings (wk 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="424"/>
                    <count group_id="O2" value="424"/>
                    <count group_id="O3" value="427"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="3.02"/>
                    <measurement group_id="O2" value="-0.32" spread="3.20"/>
                    <measurement group_id="O3" value="-0.24" spread="3.14"/>
                    <measurement group_id="O4" value="-0.22" spread="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12) Eating in response to food cravings (wk 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="436"/>
                    <count group_id="O3" value="437"/>
                    <count group_id="O4" value="446"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="2.49"/>
                    <measurement group_id="O2" value="-0.15" spread="2.78"/>
                    <measurement group_id="O3" value="-0.17" spread="2.78"/>
                    <measurement group_id="O4" value="-0.27" spread="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12) Eating in response to food cravings (wk 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="432"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="435"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="2.55"/>
                    <measurement group_id="O2" value="-0.11" spread="2.85"/>
                    <measurement group_id="O3" value="-0.25" spread="2.73"/>
                    <measurement group_id="O4" value="-0.17" spread="2.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12) Eating in response to food cravings (wk 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="424"/>
                    <count group_id="O3" value="427"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="2.67"/>
                    <measurement group_id="O2" value="0.01" spread="2.76"/>
                    <measurement group_id="O3" value="-0.17" spread="2.96"/>
                    <measurement group_id="O4" value="-0.25" spread="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>13) Cravings for chocolate (wk 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="437"/>
                    <count group_id="O2" value="437"/>
                    <count group_id="O3" value="436"/>
                    <count group_id="O4" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="2.69"/>
                    <measurement group_id="O2" value="-0.03" spread="2.93"/>
                    <measurement group_id="O3" value="-0.14" spread="2.94"/>
                    <measurement group_id="O4" value="-0.15" spread="2.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>13) Cravings for chocolate (wk 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="427"/>
                    <count group_id="O2" value="431"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="435"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="2.58"/>
                    <measurement group_id="O2" value="0.03" spread="2.93"/>
                    <measurement group_id="O3" value="0.06" spread="2.87"/>
                    <measurement group_id="O4" value="0.03" spread="2.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>13) Cravings for chocolate (wk 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="424"/>
                    <count group_id="O3" value="426"/>
                    <count group_id="O4" value="440"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="2.74"/>
                    <measurement group_id="O2" value="0.00" spread="2.87"/>
                    <measurement group_id="O3" value="0.06" spread="3.01"/>
                    <measurement group_id="O4" value="0.06" spread="3.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14) Cravings for other sweet foods (wk 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="437"/>
                    <count group_id="O2" value="436"/>
                    <count group_id="O3" value="437"/>
                    <count group_id="O4" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="2.65"/>
                    <measurement group_id="O2" value="-0.31" spread="2.91"/>
                    <measurement group_id="O3" value="-0.36" spread="2.82"/>
                    <measurement group_id="O4" value="-0.33" spread="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14) Cravings for other sweet foods (wk 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="432"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="436"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="2.79"/>
                    <measurement group_id="O2" value="-0.34" spread="2.93"/>
                    <measurement group_id="O3" value="-0.31" spread="2.96"/>
                    <measurement group_id="O4" value="-0.09" spread="2.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14) Cravings for other sweet foods (wk 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="425"/>
                    <count group_id="O3" value="427"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="2.84"/>
                    <measurement group_id="O2" value="-0.14" spread="3.01"/>
                    <measurement group_id="O3" value="-0.40" spread="2.93"/>
                    <measurement group_id="O4" value="-0.22" spread="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15) Cravings for fruit or fruit juice (wk 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="437"/>
                    <count group_id="O2" value="437"/>
                    <count group_id="O3" value="436"/>
                    <count group_id="O4" value="446"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="3.05"/>
                    <measurement group_id="O2" value="-0.03" spread="3.27"/>
                    <measurement group_id="O3" value="-0.09" spread="3.04"/>
                    <measurement group_id="O4" value="-0.07" spread="3.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15) Cravings for fruit or fruit juice (wk 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="431"/>
                    <count group_id="O3" value="432"/>
                    <count group_id="O4" value="433"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="2.99"/>
                    <measurement group_id="O2" value="-0.01" spread="3.34"/>
                    <measurement group_id="O3" value="-0.22" spread="3.07"/>
                    <measurement group_id="O4" value="-0.08" spread="3.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15) Cravings for fruit or fruit juice (wk 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="425"/>
                    <count group_id="O3" value="426"/>
                    <count group_id="O4" value="439"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="2.97"/>
                    <measurement group_id="O2" value="-0.11" spread="3.51"/>
                    <measurement group_id="O3" value="-0.02" spread="3.12"/>
                    <measurement group_id="O4" value="-0.33" spread="2.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16) Cravings for dairy foods (wk 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="437"/>
                    <count group_id="O2" value="437"/>
                    <count group_id="O3" value="437"/>
                    <count group_id="O4" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="3.06"/>
                    <measurement group_id="O2" value="-0.20" spread="2.90"/>
                    <measurement group_id="O3" value="-0.37" spread="3.02"/>
                    <measurement group_id="O4" value="-0.27" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16) Cravings for dairy foods (wk 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="427"/>
                    <count group_id="O2" value="430"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="435"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="2.96"/>
                    <measurement group_id="O2" value="-0.30" spread="2.97"/>
                    <measurement group_id="O3" value="-0.41" spread="2.86"/>
                    <measurement group_id="O4" value="0.04" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16) Cravings for dairy foods (wk 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="425"/>
                    <count group_id="O3" value="426"/>
                    <count group_id="O4" value="439"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="3.00"/>
                    <measurement group_id="O2" value="-0.20" spread="2.95"/>
                    <measurement group_id="O3" value="-0.45" spread="2.86"/>
                    <measurement group_id="O4" value="-0.20" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17) Cravings for starchy foods (wk 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="436"/>
                    <count group_id="O2" value="436"/>
                    <count group_id="O3" value="436"/>
                    <count group_id="O4" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="2.65"/>
                    <measurement group_id="O2" value="-0.24" spread="2.56"/>
                    <measurement group_id="O3" value="-0.49" spread="2.75"/>
                    <measurement group_id="O4" value="-0.42" spread="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17) Cravings for starchy foods (wk 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="426"/>
                    <count group_id="O2" value="430"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="435"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="2.86"/>
                    <measurement group_id="O2" value="-0.35" spread="2.68"/>
                    <measurement group_id="O3" value="-0.62" spread="2.80"/>
                    <measurement group_id="O4" value="-0.28" spread="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17) Cravings for starchy foods (wk 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="423"/>
                    <count group_id="O2" value="423"/>
                    <count group_id="O3" value="426"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="2.94"/>
                    <measurement group_id="O2" value="-0.32" spread="2.76"/>
                    <measurement group_id="O3" value="-0.61" spread="2.86"/>
                    <measurement group_id="O4" value="-0.36" spread="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18) Cravings for savoury foods (wk 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="437"/>
                    <count group_id="O2" value="437"/>
                    <count group_id="O3" value="437"/>
                    <count group_id="O4" value="443"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="2.74"/>
                    <measurement group_id="O2" value="-0.16" spread="2.69"/>
                    <measurement group_id="O3" value="-0.49" spread="2.85"/>
                    <measurement group_id="O4" value="-0.40" spread="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18) Cravings for savoury foods (wk 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="427"/>
                    <count group_id="O2" value="431"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="436"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="2.85"/>
                    <measurement group_id="O2" value="-0.20" spread="2.82"/>
                    <measurement group_id="O3" value="-0.56" spread="2.72"/>
                    <measurement group_id="O4" value="-0.37" spread="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18) Cravings for savoury foods (wk 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="423"/>
                    <count group_id="O2" value="422"/>
                    <count group_id="O3" value="427"/>
                    <count group_id="O4" value="440"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="2.88"/>
                    <measurement group_id="O2" value="-0.16" spread="2.87"/>
                    <measurement group_id="O3" value="-0.48" spread="2.95"/>
                    <measurement group_id="O4" value="-0.34" spread="2.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>19) Difficulty to control eating in general(wk 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="436"/>
                    <count group_id="O2" value="437"/>
                    <count group_id="O3" value="437"/>
                    <count group_id="O4" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="2.68"/>
                    <measurement group_id="O2" value="-0.69" spread="2.77"/>
                    <measurement group_id="O3" value="-0.49" spread="2.69"/>
                    <measurement group_id="O4" value="-0.51" spread="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>19) Difficulty to control eating in general(wk 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="432"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="436"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="2.76"/>
                    <measurement group_id="O2" value="-0.59" spread="2.86"/>
                    <measurement group_id="O3" value="-0.56" spread="2.75"/>
                    <measurement group_id="O4" value="-0.51" spread="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>19) Difficulty to control eating in general(wk 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="424"/>
                    <count group_id="O3" value="427"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="2.71"/>
                    <measurement group_id="O2" value="-0.59" spread="2.88"/>
                    <measurement group_id="O3" value="-0.54" spread="2.71"/>
                    <measurement group_id="O4" value="-0.51" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Craving control: items 9-12, 19 (wk 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="437"/>
                    <count group_id="O3" value="437"/>
                    <count group_id="O4" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" spread="2.13"/>
                    <measurement group_id="O2" value="0.39" spread="2.18"/>
                    <measurement group_id="O3" value="0.35" spread="2.16"/>
                    <measurement group_id="O4" value="0.35" spread="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Craving control: items 9-12, 19 (wk 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="432"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="436"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="2.20"/>
                    <measurement group_id="O2" value="0.27" spread="2.26"/>
                    <measurement group_id="O3" value="0.34" spread="2.21"/>
                    <measurement group_id="O4" value="0.29" spread="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Craving control: items 9-12, 19 (wk 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="425"/>
                    <count group_id="O3" value="427"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="2.30"/>
                    <measurement group_id="O2" value="0.29" spread="2.35"/>
                    <measurement group_id="O3" value="0.33" spread="2.29"/>
                    <measurement group_id="O4" value="0.34" spread="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive mood: items 5-8 (wk 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="438"/>
                    <count group_id="O2" value="435"/>
                    <count group_id="O3" value="437"/>
                    <count group_id="O4" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="1.51"/>
                    <measurement group_id="O2" value="0.07" spread="1.43"/>
                    <measurement group_id="O3" value="-0.01" spread="1.61"/>
                    <measurement group_id="O4" value="0.15" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive mood: items 5-8 (wk 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="431"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="436"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="1.50"/>
                    <measurement group_id="O2" value="0.03" spread="1.54"/>
                    <measurement group_id="O3" value="0.05" spread="1.60"/>
                    <measurement group_id="O4" value="0.03" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive mood: items 5-8 (wk 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="424"/>
                    <count group_id="O3" value="427"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="1.57"/>
                    <measurement group_id="O2" value="-0.07" spread="1.52"/>
                    <measurement group_id="O3" value="0.09" spread="1.55"/>
                    <measurement group_id="O4" value="0.05" spread="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Craving for savoury: items 4, 16-18 (wk 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="437"/>
                    <count group_id="O2" value="437"/>
                    <count group_id="O3" value="437"/>
                    <count group_id="O4" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="1.88"/>
                    <measurement group_id="O2" value="-0.19" spread="1.94"/>
                    <measurement group_id="O3" value="-0.41" spread="2.07"/>
                    <measurement group_id="O4" value="-0.36" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Craving for savoury: items 4, 16-18 (wk 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="432"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="436"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="2.01"/>
                    <measurement group_id="O2" value="-0.27" spread="1.95"/>
                    <measurement group_id="O3" value="-0.51" spread="2.11"/>
                    <measurement group_id="O4" value="-0.24" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Craving for savoury: items 4, 16-18 (wk 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="425"/>
                    <count group_id="O3" value="427"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="2.06"/>
                    <measurement group_id="O2" value="-0.26" spread="2.12"/>
                    <measurement group_id="O3" value="-0.48" spread="2.08"/>
                    <measurement group_id="O4" value="-0.33" spread="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Craving for sweet: items 3, 13-15 (wk 26)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="437"/>
                    <count group_id="O2" value="437"/>
                    <count group_id="O3" value="437"/>
                    <count group_id="O4" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="1.88"/>
                    <measurement group_id="O2" value="-0.23" spread="2.12"/>
                    <measurement group_id="O3" value="-0.26" spread="2.10"/>
                    <measurement group_id="O4" value="-0.22" spread="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Craving for sweet: items 3, 13-15 (wk 52)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="432"/>
                    <count group_id="O3" value="434"/>
                    <count group_id="O4" value="436"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="1.97"/>
                    <measurement group_id="O2" value="-0.15" spread="2.17"/>
                    <measurement group_id="O3" value="-0.19" spread="2.19"/>
                    <measurement group_id="O4" value="-0.15" spread="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Craving for sweet: items 3, 13-15 (wk 78)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="425"/>
                    <count group_id="O2" value="425"/>
                    <count group_id="O3" value="427"/>
                    <count group_id="O4" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="1.94"/>
                    <measurement group_id="O2" value="-0.16" spread="2.22"/>
                    <measurement group_id="O3" value="-0.20" spread="2.20"/>
                    <measurement group_id="O4" value="-0.24" spread="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Week 0 to week 83 (78 weeks treatment period + 5 weeks follow-up period). Results are based on the safety analysis set (SAS), which comprised all randomised participants who received at least one dose of trial product.</time_frame>
      <desc>Serious adverse events and other AEs were based on the on-treatment observation period, i.e., the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication. All-cause mortality were based on the in-trial observation period, i.e., the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product.</desc>
      <group_list>
        <group group_id="E1">
          <title>Oral Semaglutide 3 mg</title>
          <description>Participants were to take oral semaglutide 3 mg tablets once daily from week 0 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
        </group>
        <group group_id="E2">
          <title>Oral Semaglutide 7 mg</title>
          <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4 and 7 mg from week 4 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
        </group>
        <group group_id="E3">
          <title>Oral Semaglutide 14 mg</title>
          <description>Participants were to take oral semaglutide tablets once daily in a dose escalation manner from week 0 to week 78: 3 mg from week 0 to week 4, 7 mg from week 4 to week 8 and 14 mg from week 8 to week 78. In addition, participants were to take sitagliptin placebo tablets once daily from week 0 to week 78.</description>
        </group>
        <group group_id="E4">
          <title>Sitagliptin 100 mg</title>
          <description>Participants were to take sitagliptin 100 mg tablets once daily from week 0 to week 78. In addition, participants were to take oral semaglutide placebo tablets once daily from week 0 to week 78.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="466"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="464"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="466"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="464"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="465"/>
                <counts group_id="E4" subjects_affected="58" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="466"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="466"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Myocardial fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Exostosis of external ear canal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Hypopituitarism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Cataract diabetic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Conjunctival irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Retinopathy proliferative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Barrett's oesophagus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Pancreatic cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Complication associated with device</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Chronic hepatic failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Cirrhosis alcoholic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Non-alcoholic steatohepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Neurosyphilis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="465"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Septic phlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Testicular abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Incisional hernia, obstructive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Scapula fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Skull fractured base</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Diabetic metabolic decompensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Diabetic amyotrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="466"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="465"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Brain neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Nasal cavity cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Ovarian cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Pancreatic neuroendocrine tumour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain stem stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Chronic inflammatory demyelinating polyradiculoneuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Focal dyscognitive seizures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Thalamic infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>End stage renal disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Laparoscopic surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Umbilical hernia repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Essential hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="466"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="465"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="222" subjects_at_risk="466"/>
                <counts group_id="E2" subjects_affected="234" subjects_at_risk="464"/>
                <counts group_id="E3" subjects_affected="232" subjects_at_risk="465"/>
                <counts group_id="E4" subjects_affected="239" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="466"/>
                <counts group_id="E2" events="25" subjects_affected="24" subjects_at_risk="464"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="465"/>
                <counts group_id="E4" events="27" subjects_affected="26" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="62" subjects_affected="44" subjects_at_risk="466"/>
                <counts group_id="E2" events="81" subjects_affected="53" subjects_at_risk="464"/>
                <counts group_id="E3" events="74" subjects_affected="56" subjects_at_risk="465"/>
                <counts group_id="E4" events="44" subjects_affected="37" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="42" subjects_affected="34" subjects_at_risk="466"/>
                <counts group_id="E2" events="74" subjects_affected="62" subjects_at_risk="464"/>
                <counts group_id="E3" events="88" subjects_affected="70" subjects_at_risk="465"/>
                <counts group_id="E4" events="39" subjects_affected="31" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="466"/>
                <counts group_id="E2" events="41" subjects_affected="27" subjects_at_risk="464"/>
                <counts group_id="E3" events="82" subjects_affected="42" subjects_at_risk="465"/>
                <counts group_id="E4" events="26" subjects_affected="19" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="35" subjects_affected="29" subjects_at_risk="466"/>
                <counts group_id="E2" events="28" subjects_affected="24" subjects_at_risk="464"/>
                <counts group_id="E3" events="21" subjects_affected="18" subjects_at_risk="465"/>
                <counts group_id="E4" events="35" subjects_affected="30" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="74" subjects_affected="53" subjects_at_risk="466"/>
                <counts group_id="E2" events="65" subjects_affected="49" subjects_at_risk="464"/>
                <counts group_id="E3" events="57" subjects_affected="47" subjects_at_risk="465"/>
                <counts group_id="E4" events="69" subjects_affected="47" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="53" subjects_affected="36" subjects_at_risk="466"/>
                <counts group_id="E2" events="50" subjects_affected="35" subjects_at_risk="464"/>
                <counts group_id="E3" events="34" subjects_affected="26" subjects_at_risk="465"/>
                <counts group_id="E4" events="49" subjects_affected="32" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="32" subjects_affected="29" subjects_at_risk="466"/>
                <counts group_id="E2" events="26" subjects_affected="21" subjects_at_risk="464"/>
                <counts group_id="E3" events="30" subjects_affected="23" subjects_at_risk="465"/>
                <counts group_id="E4" events="32" subjects_affected="26" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="466"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="464"/>
                <counts group_id="E3" events="32" subjects_affected="32" subjects_at_risk="465"/>
                <counts group_id="E4" events="15" subjects_affected="14" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="21" subjects_at_risk="466"/>
                <counts group_id="E2" events="17" subjects_affected="13" subjects_at_risk="464"/>
                <counts group_id="E3" events="25" subjects_affected="20" subjects_at_risk="465"/>
                <counts group_id="E4" events="32" subjects_affected="29" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="35" subjects_affected="24" subjects_at_risk="466"/>
                <counts group_id="E2" events="31" subjects_affected="25" subjects_at_risk="464"/>
                <counts group_id="E3" events="25" subjects_affected="24" subjects_at_risk="465"/>
                <counts group_id="E4" events="35" subjects_affected="29" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="37" subjects_affected="29" subjects_at_risk="466"/>
                <counts group_id="E2" events="40" subjects_affected="30" subjects_at_risk="464"/>
                <counts group_id="E3" events="50" subjects_affected="36" subjects_at_risk="465"/>
                <counts group_id="E4" events="57" subjects_affected="36" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="32" subjects_affected="29" subjects_at_risk="466"/>
                <counts group_id="E2" events="27" subjects_affected="24" subjects_at_risk="464"/>
                <counts group_id="E3" events="26" subjects_affected="26" subjects_at_risk="465"/>
                <counts group_id="E4" events="29" subjects_affected="29" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Reporting Anchor and Disclosure (1452)</name_or_title>
      <organization>Novo Nordisk A/S</organization>
      <phone>(+1) 866-867-7178</phone>
      <email>clinicaltrials@novonordisk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

